adalimumab vs certolizumab pegol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Crohn's Diseasemonoclonal antibody (fully human IgG1)
Partial signal

NCT00055497 · Phase 3 · completed

Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.

Next expected readout: June 2027 · NCT06045754 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)

Result source: NCT02499783

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Crohn's DiseasePEGylated anti-TNF Fab' fragment
Weak signal

NCT00552344 · Phase 3 · completed

This open-label study gave long-term certolizumab pegol to patients with Crohn's disease from study C87085. Its primary objective was safety and its primary outcomes were adverse events, so there is no efficacy result to call met or missed. Over up to 272 weeks, 89.6% of patients had an adverse event and 37.1% a serious one. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Percentage of Subjects in Clinical Remission at Week 6: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported (missed)

Result source: NCT00552058

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabcertolizumab pegol
Clinical remission (induction)37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
31.6% vs 25.4%+6.2 vs placebowk 6 · n 215NCT00552058
2 other results
  • 26.5% vs 19.1% wk 4 · n 215 · Phase 3 · secondary NCT00552058
  • 23.3% vs 15.8% wk 2 · n 215 · Phase 3 · secondary NCT00552058
Endoscopic response (induction)—Trial running · NCT05040464—Not posted · NCT00152425
Clinical remission (maintenance)47.4% vs 33.3%+14.1 vs placebo40 mg every other week · wk 56 · n 19NCT00055497
11 other results
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 38.1% vs 9.1% 40 mg Eow · wk 52 · n 21 · Phase 2/3 · primary NCT00445432
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
37.5% vs 35%+2.5 vs placebowk 34 · n 16NCT00356408
1 other result
  • 3% vs 35% wk 34 · n 33 · Phase 3 · secondary NCT00356408
Endoscopic response (maintenance)—Trial running · NCT05040464—Not posted · NCT00152425

Clinical remission (induction)

adalimumab
37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
certolizumab pegol
31.6% vs 25.4%+6.2 vs placebowk 6 · n 215NCT00552058
2 other results
  • 26.5% vs 19.1% wk 4 · n 215 · Phase 3 · secondary NCT00552058
  • 23.3% vs 15.8% wk 2 · n 215 · Phase 3 · secondary NCT00552058

Endoscopic response (induction)

adalimumab
—Trial running · NCT05040464
certolizumab pegol
—Not posted · NCT00152425

Clinical remission (maintenance)

adalimumab
47.4% vs 33.3%+14.1 vs placebo40 mg every other week · wk 56 · n 19NCT00055497
11 other results
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 38.1% vs 9.1% 40 mg Eow · wk 52 · n 21 · Phase 2/3 · primary NCT00445432
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
certolizumab pegol
37.5% vs 35%+2.5 vs placebowk 34 · n 16NCT00356408
1 other result
  • 3% vs 35% wk 34 · n 33 · Phase 3 · secondary NCT00356408

Endoscopic response (maintenance)

adalimumab
—Trial running · NCT05040464
certolizumab pegol
—Not posted · NCT00152425
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. adalimumab: 11 of 11 rows · certolizumab pegol: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
certolizumab pegol
Rows use multiple source trials
CDAI
responder rate · % of participants
Induction
67.6% (n=102) vs 27.2% (n=103) placebo @ 4wk160/80 mga
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
35.3% (n=215) vs 26.3% (n=209) placebo @ 4wka
NCT00552058 · Phase 3 · monotherapy
CDAI
responder rate · % of participants
No placebo or comparator arm
83.4% (n=308) @ 12wkb,a,c
NCT02065570 · Phase 3 · monotherapy
show 1 more dose
74.8% (n=206) @ 12wk
NCT02065570 · Phase 3 · monotherapy
53.3% (n=229)400 mga,c
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1 other source trial
32.6% (n=89) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
CDAI
absolute change · score
No placebo or comparator arm
-185.24 score @ 10wkLow Induction Doseb,d,a,e,c
NCT02015793 · Phase 2 · registry result, not featured evidence
show 1 more dose
-182.87 score @ 10wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
-121.52 score400 mgd,a,e,c
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1 other source trial
-148.82 score @ 10wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Remission
responder rate · % of participants
No placebo or comparator arm
60% (n=55) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)f,a,g
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
2 other source trials
66.7% (n=15) @ 10wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 10wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
46.1% (n=89) @ 10wk400 mgf,a,g
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Endoscopic
responder rate · % of participants
No placebo or comparator arm
56.4% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)f,a,g,h
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
62.3% (n=53) @ 54wk400 mgb,f,a,g,h
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more dose
39.3% (n=28) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Endoscopic Remission
responder rate · % of participants
No placebo or comparator arm
34.5% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)f,a,g,h
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
28.3% (n=53) @ 54wk400 mgb,f,a,g,h
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more dose
32.1% (n=28) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
IBDQ Remission
responder rate · % of participants
Induction
40.2% (n=102) vs 20.4% (n=103) placebo @ 4wk160/80 mga
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
33.5% (n=215) vs 23.9% (n=209) placebo @ 4wka
NCT00552058 · Phase 3 · monotherapy
Dropout rate
—40 mg every other weeki
NCT00055497 · Phase 3
show 34 more results
15.8%40 mg every other week
NCT00055497 · Phase 3
11.1%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
40.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
48.5%
NCT00195715 · Phase 3
16.9%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.4%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
6.8%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
6.8%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
21.4%
NCT02185014 · Phase 3 · monotherapy
61%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
60%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
34.4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
35.7%80 mg
NCT01958827 · Phase 3 · monotherapy
16.4%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
36%
NCT02148718 · Phase 4 · registry result, not featured evidence
26.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
26.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
78.4%j
NCT00552344 · Phase 3 · monotherapy
show 24 more results
80.3%
NCT00160524 · Phase 3 · monotherapy
—400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
—400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
69.5%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
92.3%
NCT00160706 · Phase 3 · monotherapy
—400 mg
NCT00356408 · Phase 3 · monotherapy
—CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
—CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
7.2%
NCT00552058 · Phase 3 · monotherapy
40.4%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
46.2%400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
53.3%400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
25%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
3.1%400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weeki
NCT00055497 · Phase 3
show 34 more results
5.3%40 mg every other week
NCT00055497 · Phase 3
5.6%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
12.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
15.7%
NCT00195715 · Phase 3
6%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1.5%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
3.9%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
2.4%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
7.1%
NCT02185014 · Phase 3 · monotherapy
8%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
21.9%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
10.7%80 mg
NCT01958827 · Phase 3 · monotherapy
10.9%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
—
NCT02148718 · Phase 4 · registry result, not featured evidence
20%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
20%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—j
NCT00552344 · Phase 3 · monotherapy
show 24 more results
35.8%
NCT00160524 · Phase 3 · monotherapy
—400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
—400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
18.9%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
51%
NCT00160706 · Phase 3 · monotherapy
—400 mg
NCT00356408 · Phase 3 · monotherapy
—CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
—CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
3.6%
NCT00552058 · Phase 3 · monotherapy
14.6%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
—400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
—400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
12.5%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Serious AEs
5.3%40 mg every other weeki
NCT00055497 · Phase 3
show 34 more results
—40 mg every other week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
0%40 mg every week
NCT00055497 · Phase 3
16.7%40 mg
NCT00055497 · Phase 3
2%160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
38.1%
NCT00195715 · Phase 3
—40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
14.8%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.5%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.9%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.6%Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
6.4%Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
10.7%
NCT02185014 · Phase 3 · monotherapy
48%
NCT00686374 · Phase 3 · monotherapy
23.7%40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20%20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
8%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
40.6%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
28.6%80 mg
NCT01958827 · Phase 3 · monotherapy
—40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
2.3%
NCT02148718 · Phase 4 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
7.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
14.3%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
37.1%j
NCT00552344 · Phase 3 · monotherapy
show 24 more results
40.3%
NCT00160524 · Phase 3 · monotherapy
13.4%400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
13.4%400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
31.9%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
44.5%
NCT00160706 · Phase 3 · monotherapy
14.6%400 mg
NCT00356408 · Phase 3 · monotherapy
0%CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
12.1%CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
5.4%
NCT00552058 · Phase 3 · monotherapy
38.2%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
0%Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
40%High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
0%Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
50%Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
23.1%400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
33.3%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
31.3%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
9.4%400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weeki
nasopharyngitis 26.3% (placebo 38.9%)
crohn's disease aggravated 21.1% (placebo 27.8%)
sinusitis 21.1% (placebo 5.6%)
NCT00055497 · Phase 3
show 28 more results
40 mg every week
crohn's disease aggravated 11.1% (placebo 27.8%)
dizziness (excl vertigo) 11.1% (placebo 5.6%)
nasopharyngitis 11.1% (placebo 38.9%)
NCT00055497 · Phase 3
40 mg
crohn's disease aggravated 17.6% (placebo 27.8%)
nasopharyngitis 16.7% (placebo 38.9%)
headache 14% (placebo 11.1%)
NCT00055497 · Phase 3
160/80 mg
white blood cell count decreased 5.9% (placebo 1%)
cough 4.9% (placebo 0%)
dizziness 3.9% (placebo 0%)
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 39.8%
nasopharyngitis 26.1%
arthralgia 24.7%
NCT00195715 · Phase 3
40 mg every other week or every week
headache 18.9%
nasopharyngitis 14.4%
arthralgia 7.6%
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 23.4% (placebo 29.2%)
headache 14.1% (placebo 9.2%)
nasopharyngitis 14.1% (placebo 12.3%)
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
nasopharyngitis 6.2%
headache 5.5%
crohn's disease 4.5%
NCT02065570 · Phase 3 · monotherapy
headache 8.7%
arthralgia 7.8%
nausea 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 14.7%
nasopharyngitis 13.8%
headache 8.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 13.8%
nasopharyngitis 9.2%
headache 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 11.9%
arthralgia 7.1%
nausea 6%
NCT02185014 · Phase 3 · monotherapy
viral upper respiratory tract infection 39%
headache 37%
upper respiratory tract infection 31%
NCT00686374 · Phase 3 · monotherapy
40 mg or 20 mg every other week
headache 17.2%
crohn's disease 11.8%
nausea 10.8%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20 mg or 10 mg every other week
headache 21.1%
crohn's disease 15.8%
nasopharyngitis 11.6%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
40 mg Eow
nasopharyngitis 56% (placebo 12%)
rhinorrhoea 16% (placebo 0%)
adverse drug reaction 12% (placebo 4%)
NCT00445432 · Phase 2/3 · monotherapy
40 mg Eow
nasopharyngitis 71.9% (placebo 12%)
adverse drug reaction 18.8% (placebo 4%)
iron deficiency anaemia 18.8% (placebo 0%)
NCT00445432 · Phase 2/3 · monotherapy
160 mg/80 mg + 40/40 mg
adverse drug reaction 11.1% (placebo 4.3%)
application site swelling 11.1% (placebo 0%)
blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
160 mg/80 mg
headache 9.1% (placebo 4.3%)
upper respiratory tract infection 9.1% (placebo 4.3%)
abdominal distension 6.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80/40 mg + 40/40 mg
headache 16.7% (placebo 4.3%)
abdominal distension 8.3% (placebo 0%)
abdominal pain 8.3% (placebo 4.3%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg/40 mg
injection site reaction 8.8% (placebo 8.7%)
malaise 8.8% (placebo 0%)
rhinorrhoea 8.8% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg
nasopharyngitis 46.4%
rash 14.3%
headache 10.7%
NCT01958827 · Phase 3 · monotherapy
40 mg every other week
crohn's disease 16.1%
abdominal pain 7.6%
injection site reaction 7.6%
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
arthralgia 18.2%
crohn's disease 16.4%
nasopharyngitis 10.9%
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
vomiting 7%
abdominal mass 5.8%
arthralgia 4.7%
NCT02148718 · Phase 4 · registry result, not featured evidence
Low Induction Dose
leukopenia 20%
pyrexia 13.3%
arthralgia 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Low Induction Dose
leukopenia 15.4%
animal bite 7.7%
aphthous stomatitis 7.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
alanine aminotransferase increased 13.3%
aspartate aminotransferase increased 13.3%
abdominal pain 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
mycobacterium tuberculosis complex test positive 14.3%
aspartate aminotransferase increased 7.1%
asthenia 7.1%
NCT02015793 · Phase 2 · registry result, not featured evidence
j
crohn's disease 31.6%
abdominal pain 18.7%
upper respiratory tract infection 15.7%
NCT00552344 · Phase 3 · monotherapy
show 21 more results
crohn's disease 21.8%
nasopharyngitis 15.3%
abdominal pain 15%
NCT00160524 · Phase 3 · monotherapy
400 mg every 2 weeks
nasopharyngitis 17.2%
pyrexia 11.8%
arthralgia 10.8%
NCT00308581 · Phase 3 · monotherapy
400 mg every 4 weeks
headache 16.6%
nasopharyngitis 12.3%
nausea 11.2%
NCT00308581 · Phase 3 · monotherapy
400 mg
nasopharyngitis 27.5%
headache 20.5%
pyrexia 20.5%
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 34.5%
abdominal pain 20%
arthralgia 15.8%
NCT00160706 · Phase 3 · monotherapy
400 mg
crohn's disease 21.4% (placebo 7.1%)
arthralgia 18.4% (placebo 0%)
upper respiratory tract infection 13.6% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
arthralgia 25% (placebo 0%)
myalgia 18.8% (placebo 0%)
sinusitis 18.8% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
crohn's disease 33.3% (placebo 7.1%)
arthralgia 21.2% (placebo 0%)
nausea 18.2% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
headache 5.4% (placebo 4.7%)
abdominal pain 4.5% (placebo 3.7%)
arthralgia 4% (placebo 2.8%)
NCT00552058 · Phase 3 · monotherapy
400 mg
headache 33.7%
arthralgia 30.3%
nasopharyngitis 23.6%
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
High-dose (Weight Adjusted)
abdominal pain upper 40%
nasopharyngitis 20%
nausea 20%
NCT01190410 · Phase 2 · registry result, not featured evidence
Low-dose (Weight Adjusted)
asthma exercise induced 25%
cough 25%
dizziness 25%
NCT01190410 · Phase 2 · registry result, not featured evidence
Re-Induction
abdominal injury 50%
anal fissure 50%
c-reactive protein increased 50%
NCT01190410 · Phase 2 · registry result, not featured evidence
400 mg / 200 mg
pyrexia 46.2% (placebo 11.1%)
nasopharyngitis 38.5% (placebo 55.6%)
contusion 15.4% (placebo 0%)
NCT00329420 · Phase 2 · registry result, not featured evidence
400 mg / 400 mg
nasopharyngitis 40% (placebo 55.6%)
pyrexia 20% (placebo 11.1%)
nausea 13.3% (placebo 5.6%)
NCT00329420 · Phase 2 · registry result, not featured evidence
nasopharyngitis 20% (placebo 22.2%)
nausea 13.3% (placebo 22.2%)
urinary tract infection 13.3% (placebo 0%)
NCT00329550 · Phase 2 · registry result, not featured evidence
nasopharyngitis 62.5% (placebo 22.2%)
dna antibody positive 12.5% (placebo 22.2%)
headache 12.5% (placebo 0%)
NCT00329550 · Phase 2 · registry result, not featured evidence
400 mg
nasopharyngitis 21.9% (placebo 31.3%)
nausea 6.3% (placebo 3.1%)
pharynx discomfort 6.3% (placebo 0%)
NCT00291668 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 23.3% (placebo 31.3%)
nausea 6.7% (placebo 3.1%)
pharyngolaryngeal pain 6.7% (placebo 0%)
NCT00291668 · Phase 2 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  3. cThe assessment timepoint is not available for both results.
  4. dTrial phases differ: Phase 2 versus Phase 3.
  5. eTreatment context has not been resolved for both arms.
  6. fTrial phases differ: Phase 4 versus Phase 3.
  7. gTreatment context differs: combination versus monotherapy.
  8. hAssessment timepoints differ: 26 weeks versus 54 weeks.
  9. iPopulation comparability has not been reviewed for 24 of these studies.
  10. jPopulation comparability has not been reviewed for 21 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

CR-100 57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
show 11 more results
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
CR-70 68.4% (n=19) vs 44.4% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
show 11 more results
94.4% (n=18) vs 44.4% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
60.3% (n=204) vs 44.4% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 123 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
53.9% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
94.7% (n=19) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 18 Participants as posted
94.4% (n=18) vs 83.3% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
70.6% (n=204) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 144 Participants as posted
78.9% (n=19) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
88.9% (n=18) vs 72.2% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 16 Participants as posted
72.1% (n=204) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 147 Participants as posted
IBDQ 43.4 vs 29.9 placebo score @ 24wk40 mg every other week
absolute change · score
Maintenance
NCT00055497 · Phase 3
show 6 more results
51.9 vs 29.9 placebo score @ 24wk40 mg every week
NCT00055497 · Phase 3
33.9 vs 29.9 placebo score @ 24wk40 mg every other week
NCT00055497 · Phase 3
45.7 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
45.2 vs 24.7 placebo score @ 56wk40 mg every week
NCT00055497 · Phase 3
36 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
27.8 vs 1.8 placebo score @ 52wk40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
Clinical Response 100 85.7% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Clinical Response 70 91.2% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Corticosteroid-free Clinical Remission 50% (n=16) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
responder rate · % of participants
No placebo or comparator arm
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
56.3% (n=16) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
63.1% (n=103) @ 156wk
NCT00195715 · Phase 3
48% (n=100) @ 12wk
NCT02065570 · Phase 3 · monotherapy
52.9% (n=155) @ 12wk
NCT02065570 · Phase 3 · monotherapy
Steroid-free Clinical Response 100 74.8% (n=103) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Fistula Remission 55.8% (n=43) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Clinical Remission 52.1% (n=945) @ 20wk40 mg every other week or every week
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 492 Participants as posted
show 1 more result
15.6% (n=32) @ 52wk*40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy · converted to % from 5 Participants as posted
HBI 69.6% (n=945) @ 20wk40 mg every other week or every week
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 658 Participants as posted
Fistula 35.8% (n=148) @ 20wk40 mg every other week or every week
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 53 Participants as posted
SIBDQ 13.2 score @ 20wk40 mg every other week or every week
absolute change · score
Maintenance
No placebo or comparator arm
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3

+ 53 further endpoints in the CSV export.

certolizumab pegol

HBI 21.7% (n=594) @ 364wk
responder rate · % of participants
No placebo or comparator arm
NCT00160524 · Phase 3 · monotherapy
show 2 more results
52.8% (n=307) @ 362wk
NCT00160706 · Phase 3 · monotherapy
65.6% (n=299) @ 362wk
NCT00160706 · Phase 3 · monotherapy
CDAI-100 37.4% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 70 participants as posted
show 1 more result
35.5% (n=186) @ 26wk*400 mg every 2 weeks
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 66 participants as posted
CDAI-70 40.1% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 75 participants as posted
show 1 more result
40.3% (n=186) @ 26wk*400 mg every 2 weeks
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 75 participants as posted
Clinical Remission 27.3% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Remission
NCT00308581 · Phase 3 · monotherapy · converted to % from 51 participants as posted
show 1 more result
28% (n=186) @ 26wk*400 mg every 2 weeks
Remission
NCT00308581 · Phase 3 · monotherapy · converted to % from 52 participants as posted
CDAI 175.62 score @ 8wk400 mg every 4 weeks
absolute value · score
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy
show 19 more results
169.18 score @ 8wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
164.65 score @ 10wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
162.86 score @ 10wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
173.83 score @ 12wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
163.78 score @ 12wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
162.34 score @ 14wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
158.68 score @ 14wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
163.73 score @ 16wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
156.05 score @ 16wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
153.38 score @ 18wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
156.64 score @ 18wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
162.79 score @ 20wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
138.6 score @ 20wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
128.13 score @ 22wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
141.89 score @ 22wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
135.49 score @ 24wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
139.5 score @ 24wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
122.37 score @ 26wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
131.41 score @ 26wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
CDAI -133.35 score @ 8wk400 mg every 4 weeks
absolute change · score
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy
show 19 more results
-137.7 score @ 8wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-145.16 score @ 10wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-145.26 score @ 10wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-134.51 score @ 12wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-145.17 score @ 12wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-145.54 score @ 14wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.08 score @ 14wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-141.9 score @ 16wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.89 score @ 16wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-150.38 score @ 18wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.66 score @ 18wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-139.98 score @ 20wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-162.85 score @ 20wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-171.52 score @ 22wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-159.13 score @ 22wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-165.06 score @ 24wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-160.44 score @ 24wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-176.85 score @ 26wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-168.59 score @ 26wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
Duration of Response 4.21 months400 mg every 4 weeks
time to event · months
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to months from 128 days as posted
show 1 more result
4.11 months*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to months from 125 days as posted
Steroid-free Remission 2.6% (n=76) @ 10wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
show 17 more results
2.6% (n=78) @ 10wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
3.9% (n=76) @ 12wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
5.1% (n=78) @ 12wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
3.9% (n=76) @ 14wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
3.8% (n=78) @ 14wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
6.6% (n=76) @ 16wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.3% (n=78) @ 16wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
9.2% (n=76) @ 18wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
9% (n=78) @ 18wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
10.5% (n=76) @ 20wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
7.7% (n=78) @ 20wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 6 participants as posted
10.5% (n=76) @ 22wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
9% (n=78) @ 22wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
11.8% (n=76) @ 24wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
6.4% (n=78) @ 24wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.5% (n=76) @ 26wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
6.4% (n=78) @ 26wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
Steroid Free 2.6% (n=76) @ 10wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
show 17 more results
2.6% (n=78) @ 10wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
5.3% (n=76) @ 12wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
5.1% (n=78) @ 12wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
6.6% (n=76) @ 14wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
6.4% (n=78) @ 14wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.5% (n=76) @ 16wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
12.8% (n=78) @ 16wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 10 participants as posted
11.8% (n=76) @ 18wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
10.3% (n=78) @ 18wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
11.8% (n=76) @ 20wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
9% (n=78) @ 20wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
11.8% (n=76) @ 22wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
10.3% (n=78) @ 22wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
14.5% (n=76) @ 24wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 11 participants as posted
6.4% (n=78) @ 24wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
13.2% (n=76) @ 26wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 10 participants as posted
7.7% (n=78) @ 26wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 6 participants as posted
Maintenance of 61.8% (n=166)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Remission 40.6% (n=229)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Time to Loss of Response 5.57 months400 mg
time to event · months
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to months from 169.5 days as posted

+ 19 further endpoints in the CSV export.

Psoriatic Arthritis

Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Psoriatic Arthritismonoclonal antibody (fully human IgG1)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07398651 (registry estimate)

No aligned efficacy figure on record for this race.

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Psoriatic ArthritisPEGylated anti-TNF Fab' fragment
Weak signal

NCT03357471 · Phase 3 · completed

Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.

No aligned efficacy figure on record for this race.

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabcertolizumab pegol
ACR20—Not posted · NCT0064617851.9% vs 24.3%+27.6 vs placebo400 mg Q4W · wk 12 · n 135NCT01087788
3 other results
  • 58% vs 24.3% 200 mg Q2W · wk 12 · n 138 · Phase 3 · primary NCT01087788
  • 56.3% vs 23.5% 400 mg Q4W · wk 24 · n 135 · Phase 3 · secondary NCT01087788
  • 63.8% vs 23.5% 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788
ACR50—Not posted · NCT00646178—Not reported
PASI 75—Not posted · NCT0064617860.5% vs 15.1%+45.4 vs placebo400 mg Q4W · wk 24 · n 76NCT01087788
1 other result
  • 62.2% vs 15.1% 200 mg Q2W · wk 24 · n 90 · Phase 3 · secondary NCT01087788
Minimal disease activity41.5% vs 13.1%vs MTXwk 16 · n 123NCT02814175
7 other results
  • 53.8% vs 52.4% wk 48 · n 65 · Phase 4 · secondary NCT03739853
  • 46.2% vs 36.5% wk 36 · n 65 · Phase 4 · secondary NCT03739853
  • 54.9% vs 66.7% wk 32 · n 91 · Phase 4 · secondary NCT02814175
  • 80.4% vs 66.7% wk 32 · n 51 · Phase 4 · secondary NCT02814175
  • 29.8% vs 66.7% wk 32 · n 57 · Phase 4 · secondary NCT02814175
  • 55.4% vs 57.1% wk 24 · n 65 · Phase 4 · secondary NCT03739853
  • 64.6% vs 63.5% wk 12 · n 65 · Phase 4 · secondary NCT03739853
—Not reported
HAQ-DI, change-0.5 vs -0.3vs MTXwk 16 · n 116NCT02814175-0.5 vs -0.2−0.3 vs placebo400 mg Q4W · wk 24 · n 135NCT01087788
1 other result
  • -0.5 vs -0.2 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788

ACR20

adalimumab
—Not posted · NCT00646178
certolizumab pegol
51.9% vs 24.3%+27.6 vs placebo400 mg Q4W · wk 12 · n 135NCT01087788
3 other results
  • 58% vs 24.3% 200 mg Q2W · wk 12 · n 138 · Phase 3 · primary NCT01087788
  • 56.3% vs 23.5% 400 mg Q4W · wk 24 · n 135 · Phase 3 · secondary NCT01087788
  • 63.8% vs 23.5% 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788

ACR50

adalimumab
—Not posted · NCT00646178
certolizumab pegol
—Not reported

PASI 75

adalimumab
—Not posted · NCT00646178
certolizumab pegol
60.5% vs 15.1%+45.4 vs placebo400 mg Q4W · wk 24 · n 76NCT01087788
1 other result
  • 62.2% vs 15.1% 200 mg Q2W · wk 24 · n 90 · Phase 3 · secondary NCT01087788

Minimal disease activity

adalimumab
41.5% vs 13.1%vs MTXwk 16 · n 123NCT02814175
7 other results
  • 53.8% vs 52.4% wk 48 · n 65 · Phase 4 · secondary NCT03739853
  • 46.2% vs 36.5% wk 36 · n 65 · Phase 4 · secondary NCT03739853
  • 54.9% vs 66.7% wk 32 · n 91 · Phase 4 · secondary NCT02814175
  • 80.4% vs 66.7% wk 32 · n 51 · Phase 4 · secondary NCT02814175
  • 29.8% vs 66.7% wk 32 · n 57 · Phase 4 · secondary NCT02814175
  • 55.4% vs 57.1% wk 24 · n 65 · Phase 4 · secondary NCT03739853
  • 64.6% vs 63.5% wk 12 · n 65 · Phase 4 · secondary NCT03739853
certolizumab pegol
—Not reported

HAQ-DI, change

adalimumab
-0.5 vs -0.3vs MTXwk 16 · n 116NCT02814175
certolizumab pegol
-0.5 vs -0.2−0.3 vs placebo400 mg Q4W · wk 24 · n 135NCT01087788
1 other result
  • -0.5 vs -0.2 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · certolizumab pegol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumabcertolizumab pegol
Dropout rate
4.6%a
NCT03739853 · Phase 4 · registry result, not featured evidence
show 4 more results
4.9%Part 1: ADA + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Part 2: ADA
NCT02814175 · Phase 4 · registry result, not featured evidence
—Part 2: ADA + MTX Escalated Dose
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Part 2: ADA ew + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—400 mg Q4Wb
NCT01087788 · Phase 3
show 6 more results
—200 mg Q2W
NCT01087788 · Phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT03739853 · Phase 4 · registry result, not featured evidence
show 4 more results
2.4%Part 1: ADA + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Part 2: ADA
NCT02814175 · Phase 4 · registry result, not featured evidence
—Part 2: ADA + MTX Escalated Dose
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Part 2: ADA ew + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—400 mg Q4Wb
NCT01087788 · Phase 3
show 6 more results
—200 mg Q2W
NCT01087788 · Phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Serious AEs
3.1%a
NCT03739853 · Phase 4 · registry result, not featured evidence
show 4 more results
1.6%Part 1: ADA + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
1.9%Part 2: ADA
NCT02814175 · Phase 4 · registry result, not featured evidence
3.2%Part 2: ADA + MTX Escalated Dose
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
4.8%Part 2: ADA ew + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
26.2%400 mg Q4Wb
NCT01087788 · Phase 3
show 6 more results
24.7%200 mg Q2W
NCT01087788 · Phase 3
0%Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
liver function test abnormalities 27.7%
nausea 23.1%
diarrhoea 9.2%
NCT03739853 · Phase 4 · registry result, not featured evidence
show 4 more results
headache 8.1%
upper respiratory tract infection 8.1%
cough 5.7%
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 3.7%
alanine aminotransferase increased 1.9%
back pain 1.9%
NCT02814175 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 13.7%
nasopharyngitis 6.3%
nausea 4.2%
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 14.3%
back pain 6.3%
psoriatic arthropathy 6.3%
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
400 mg Q4Wb
upper respiratory tract infection 25.1%
nasopharyngitis 21.5%
pharyngitis 13.8%
NCT01087788 · Phase 3
show 3 more results
200 mg Q2W
nasopharyngitis 22.7%
upper respiratory tract infection 22.2%
hypertension 15.2%
NCT01087788 · Phase 3
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

PASDAS 3.6 vs 4 Combination csDMARD score @ 24wk
absolute value · score
NCT03739853 · Phase 4 · registry result, not featured evidence
show 1 more result
3.5 vs 3.8 Combination csDMARD score @ 48wk
NCT03739853 · Phase 4 · registry result, not featured evidence
MDA 64.6% (n=65) vs 63.5% (n=63) Combination csDMARD @ 12wk
responder rate · % of participants
NCT03739853 · Phase 4 · registry result, not featured evidence · converted to % from 42 Participants as posted
show 7 more results
55.4% (n=65) vs 57.1% (n=63) Combination csDMARD @ 24wk*
NCT03739853 · Phase 4 · registry result, not featured evidence · converted to % from 36 Participants as posted
46.2% (n=65) vs 36.5% (n=63) Combination csDMARD @ 36wk*
NCT03739853 · Phase 4 · registry result, not featured evidence · converted to % from 30 Participants as posted
53.8% (n=65) vs 52.4% (n=63) Combination csDMARD @ 48wk*
NCT03739853 · Phase 4 · registry result, not featured evidence · converted to % from 35 Participants as posted
41.5% (n=123) vs 13.1% (n=122) MTX @ 16wk
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
54.9% (n=91) vs 66.7% (n=15) MTX @ 32wk
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
80.4% (n=51) vs 66.7% (n=15) MTX @ 32wk
NCT02814175 · Phase 4 · registry result, not featured evidence
29.8% (n=57) vs 66.7% (n=15) MTX @ 32wk
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
PsAID-12 3.5 vs 4.4 Combination csDMARD score @ 12wk
absolute value · score
NCT03739853 · Phase 4 · registry result, not featured evidence
show 3 more results
3.1 vs 3.5 Combination csDMARD score @ 24wk
NCT03739853 · Phase 4 · registry result, not featured evidence
3.3 vs 2.9 Combination csDMARD score @ 36wk
NCT03739853 · Phase 4 · registry result, not featured evidence
3 vs 3.3 Combination csDMARD score @ 48wk
NCT03739853 · Phase 4 · registry result, not featured evidence
DLQI -5.9 vs -3.1 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
Dactylitis -2.8 vs -0.9 MTX count @ 16wk
absolute change · count
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
DAS28-CRP -2 vs -0.9 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
PsAID -3.3 vs -1.7 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
ACR20 67.5% (n=123) vs 32.8% (n=122) MTX @ 16wk
responder rate · % of participants
ACR 20
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
ACR50 45.5% (n=123) vs 16.4% (n=122) MTX @ 16wk
responder rate · % of participants
ACR 50
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
ACR70 30.9% (n=123) vs 8.2% (n=122) MTX @ 16wk
responder rate · % of participants
ACR 70
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
Leeds Enthesitis Index -1.9 vs -1.1 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
PASDAS -2.8 vs -1.2 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination

+ 6 further endpoints in the CSV export.

certolizumab pegol

ACR20 51.9% (n=135) vs 24.3% (n=136) placebo @ 12wk400 mg Q4W
responder rate · % of participants
NCT01087788 · Phase 3
show 3 more results
56.3% (n=135) vs 23.5% (n=136) placebo @ 24wk400 mg Q4W
NCT01087788 · Phase 3
58% (n=138) vs 24.3% (n=136) placebo @ 12wk200 mg Q2W
NCT01087788 · Phase 3
63.8% (n=138) vs 23.5% (n=136) placebo @ 24wk200 mg Q2W
NCT01087788 · Phase 3
Modified Sharp 25.05 vs 28.92 placebo score @ 24wk400 mg Q4W
absolute change · score
Pre-defined results
NCT01087788 · Phase 3
show 1 more result
11.52 vs 28.92 placebo score @ 24wk200 mg Q2W
Pre-defined results
NCT01087788 · Phase 3
PASI 75 60.5% (n=76) vs 15.1% (n=86) placebo @ 24wk400 mg Q4W
responder rate · % of participants
NCT01087788 · Phase 3
show 1 more result
62.2% (n=90) vs 15.1% (n=86) placebo @ 24wk200 mg Q2W
NCT01087788 · Phase 3
Modified Sharp 0.11 vs 0.32 placebo score @ 48wk400 mg Q4W
absolute change · score
Predefined results: Overall
NCT01087788 · Phase 3
show 1 more result
0.15 vs 0.32 placebo score @ 48wk200 mg Q2W
Predefined results: Overall
NCT01087788 · Phase 3

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Psoriasismonoclonal antibody (fully human IgG1)
Partial signal

NCT00195676 · Phase 3 · completed

Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.

Next expected readout: April 2028 · NCT07529925 (registry estimate)

Reported efficacy

Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) (not_applicable)

Result source: NCT00195676

certolizumab pegol · Cimzia

Marketed by UCB

Approved in PsoriasisPEGylated anti-TNF Fab' fragment
Reliable signal

NCT02326272 · Phase 3 · completed

This was a randomized, double-blind (quadruple-masked), placebo-controlled trial in 227 adults with moderate-to-severe plaque psoriasis. Both the 200 mg and 400 mg certolizumab pegol doses produced significantly higher rates of skin clearance (PASI75: 81.4% and 82.6% vs 11.6% placebo) and physician-assessed clearance (66.8% and 71.6% vs 2.0% placebo) at week 16, both p<0.0001.

Next expected readout: June 2030 · NCT07352566 (registry estimate)

Reported efficacy

Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16; Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 16: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo). (met)

Result source: NCT02326298

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabcertolizumab pegol
PASI 7577.8% vs 11.5%+66.3 vs placeboEow · wk 12 · n 338NCT01646073
7 other results
  • 80.1% vs 79% wk 16 · n 267 · Phase 3 · primary NCT02581345
  • 57.9% vs 32.4% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · primary NCT01251614
  • 43.6% vs 32.4% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 45.3% vs 2.3% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 9.8% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 30.6% vs 8.7% wk 16 · n 49 · Phase 4 · secondary NCT00735787
  • 67% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
82.6% vs 11.6%+71 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
11 other results
  • 75.8% vs 6.5% 400 mg Q2W · wk 16 · n 88 · Phase 3 · primary NCT02326298
  • 66.7% vs 5% 400 mg Q2W · wk 12 · n 167 · Phase 3 · primary NCT02346240
  • 87.1% vs 7.9% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · primary NCT03051217
  • 81.4% vs 11.6% 200 mg Q2W · wk 16 · n 91 · Phase 3 · primary NCT02326272
  • 66.5% vs 6.5% 200 mg Q2W · wk 16 · n 95 · Phase 3 · primary NCT02326298
  • 61.3% vs 5% 200 mg Q2W · wk 12 · n 165 · Phase 3 · primary NCT02346240
  • 73% vs 7.9% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · primary NCT03051217
  • 74.7% vs 3.8% 400 mg Q2W · wk 16 · n 167 · Phase 3 · secondary NCT02346240
  • 68.2% vs 3.8% 200 mg Q2W · wk 16 · n 165 · Phase 3 · secondary NCT02346240
  • 82.8% vs 6.8% 400 mg · wk 12 · n 58 · Phase 2 · primary NCT00245765
  • 74.6% vs 6.8% 200 mg · wk 12 · n 59 · Phase 2 · primary NCT00245765
PASI 9061.8% vs 54.2%vs EU RPPwk 16 · n 267NCT02581345
3 other results
  • 28.9% vs 21.6% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · secondary NCT01251614
  • 30.8% vs 21.6% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 20.4% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
55.4% vs 4.5%+50.9 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
11 other results
  • 43.6% vs 0.4% 400 mg Q2W · wk 16 · n 88 · Phase 3 · secondary NCT02326298
  • 49.1% vs 0.3% 400 mg Q2W · wk 16 · n 167 · Phase 3 · secondary NCT02346240
  • 34% vs 0.2% 400 mg Q2W · wk 12 · n 167 · Phase 3 · secondary NCT02346240
  • 75.7% vs 0.2% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • 52.6% vs 4.5% 200 mg Q2W · wk 16 · n 91 · Phase 3 · secondary NCT02326272
  • 35.8% vs 0.4% 200 mg Q2W · wk 16 · n 95 · Phase 3 · secondary NCT02326298
  • 39.8% vs 0.3% 200 mg Q2W · wk 16 · n 165 · Phase 3 · secondary NCT02346240
  • 31.2% vs 0.2% 200 mg Q2W · wk 12 · n 165 · Phase 3 · secondary NCT02346240
  • 53.8% vs 0.2% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  • 46.6% vs 1.7% 400 mg · wk 12 · n 58 · Phase 2 · secondary NCT00245765
  • 39% vs 1.7% 200 mg · wk 12 · n 59 · Phase 2 · secondary NCT00245765
PASI 10018.4% vs 2.7%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
2 other results
  • 10.3% vs 2.7% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 14.3% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
—Not posted · NCT04123795
sPGA 0/160.5% vs 40.5%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
11 other results
  • 41% vs 40.5% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 80.5% vs 14.9% Eow · wk 12 · n 338 · Phase 3 · secondary NCT01646073
  • 57.4% vs 4.6% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 20.1% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 68.9% vs 66.1% wk 16 · n 267 · Phase 3 · secondary NCT02581345
  • 30.6% vs 4.3% wk 16 · n 49 · Phase 4 · primary NCT00735787
  • 28.6% vs 13% wk 12 · n 49 · Phase 4 · secondary NCT00735787
  • 24.5% vs 8.7% wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • 20.4% vs 4.3% wk 4 · n 49 · Phase 4 · secondary NCT00735787
  • 8.2% vs 4.3% wk 2 · n 49 · Phase 4 · secondary NCT00735787
  • 73% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
57.9% vs 4.2%+53.7 vs placebo400 mg Q2W · wk 16 · n 88NCT02326298
5 other results
  • 47% vs 4.2% 200 mg Q2W · wk 16 · n 95 · Phase 3 · primary NCT02326298
  • 66.7% vs 0% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • 52.7% vs 0% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  • 72.4% vs 1.7% 400 mg · wk 12 · n 58 · Phase 2 · primary NCT00245765
  • 52.5% vs 1.7% 200 mg · wk 12 · n 59 · Phase 2 · primary NCT00245765
DLQI, change-4.8 vs -4.2−0.6 vs placebowk 16 · n 49NCT00735787
3 other results
  • -7.9 vs -3.7 wk 12 · n 33 · Phase 4 · secondary NCT01553058
  • -4.1 vs -3.1 wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • -4.3 vs -3.4 wk 2 · n 49 · Phase 4 · secondary NCT00735787
-10 vs -3.8−6.2 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
5 other results
  • -10.2 vs -3.3 400 mg Q2W · wk 16 · n 88 · Phase 3 · secondary NCT02326298
  • -6.8 vs -0.3 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • -10.4 vs -3.8 200 mg Q2W · wk 16 · n 90 · Phase 3 · secondary NCT02326272
  • -9.3 vs -3.3 200 mg Q2W · wk 16 · n 95 · Phase 3 · secondary NCT02326298
  • -6.8 vs -0.3 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217

PASI 75

adalimumab
77.8% vs 11.5%+66.3 vs placeboEow · wk 12 · n 338NCT01646073
7 other results
  • 80.1% vs 79% wk 16 · n 267 · Phase 3 · primary NCT02581345
  • 57.9% vs 32.4% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · primary NCT01251614
  • 43.6% vs 32.4% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 45.3% vs 2.3% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 9.8% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 30.6% vs 8.7% wk 16 · n 49 · Phase 4 · secondary NCT00735787
  • 67% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
certolizumab pegol
82.6% vs 11.6%+71 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
11 other results
  • 75.8% vs 6.5% 400 mg Q2W · wk 16 · n 88 · Phase 3 · primary NCT02326298
  • 66.7% vs 5% 400 mg Q2W · wk 12 · n 167 · Phase 3 · primary NCT02346240
  • 87.1% vs 7.9% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · primary NCT03051217
  • 81.4% vs 11.6% 200 mg Q2W · wk 16 · n 91 · Phase 3 · primary NCT02326272
  • 66.5% vs 6.5% 200 mg Q2W · wk 16 · n 95 · Phase 3 · primary NCT02326298
  • 61.3% vs 5% 200 mg Q2W · wk 12 · n 165 · Phase 3 · primary NCT02346240
  • 73% vs 7.9% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · primary NCT03051217
  • 74.7% vs 3.8% 400 mg Q2W · wk 16 · n 167 · Phase 3 · secondary NCT02346240
  • 68.2% vs 3.8% 200 mg Q2W · wk 16 · n 165 · Phase 3 · secondary NCT02346240
  • 82.8% vs 6.8% 400 mg · wk 12 · n 58 · Phase 2 · primary NCT00245765
  • 74.6% vs 6.8% 200 mg · wk 12 · n 59 · Phase 2 · primary NCT00245765

PASI 90

adalimumab
61.8% vs 54.2%vs EU RPPwk 16 · n 267NCT02581345
3 other results
  • 28.9% vs 21.6% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · secondary NCT01251614
  • 30.8% vs 21.6% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 20.4% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
certolizumab pegol
55.4% vs 4.5%+50.9 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
11 other results
  • 43.6% vs 0.4% 400 mg Q2W · wk 16 · n 88 · Phase 3 · secondary NCT02326298
  • 49.1% vs 0.3% 400 mg Q2W · wk 16 · n 167 · Phase 3 · secondary NCT02346240
  • 34% vs 0.2% 400 mg Q2W · wk 12 · n 167 · Phase 3 · secondary NCT02346240
  • 75.7% vs 0.2% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • 52.6% vs 4.5% 200 mg Q2W · wk 16 · n 91 · Phase 3 · secondary NCT02326272
  • 35.8% vs 0.4% 200 mg Q2W · wk 16 · n 95 · Phase 3 · secondary NCT02326298
  • 39.8% vs 0.3% 200 mg Q2W · wk 16 · n 165 · Phase 3 · secondary NCT02346240
  • 31.2% vs 0.2% 200 mg Q2W · wk 12 · n 165 · Phase 3 · secondary NCT02346240
  • 53.8% vs 0.2% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  • 46.6% vs 1.7% 400 mg · wk 12 · n 58 · Phase 2 · secondary NCT00245765
  • 39% vs 1.7% 200 mg · wk 12 · n 59 · Phase 2 · secondary NCT00245765

PASI 100

adalimumab
18.4% vs 2.7%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
2 other results
  • 10.3% vs 2.7% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 14.3% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
certolizumab pegol
—Not posted · NCT04123795

sPGA 0/1

adalimumab
60.5% vs 40.5%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
11 other results
  • 41% vs 40.5% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 80.5% vs 14.9% Eow · wk 12 · n 338 · Phase 3 · secondary NCT01646073
  • 57.4% vs 4.6% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 20.1% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 68.9% vs 66.1% wk 16 · n 267 · Phase 3 · secondary NCT02581345
  • 30.6% vs 4.3% wk 16 · n 49 · Phase 4 · primary NCT00735787
  • 28.6% vs 13% wk 12 · n 49 · Phase 4 · secondary NCT00735787
  • 24.5% vs 8.7% wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • 20.4% vs 4.3% wk 4 · n 49 · Phase 4 · secondary NCT00735787
  • 8.2% vs 4.3% wk 2 · n 49 · Phase 4 · secondary NCT00735787
  • 73% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
certolizumab pegol
57.9% vs 4.2%+53.7 vs placebo400 mg Q2W · wk 16 · n 88NCT02326298
5 other results
  • 47% vs 4.2% 200 mg Q2W · wk 16 · n 95 · Phase 3 · primary NCT02326298
  • 66.7% vs 0% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • 52.7% vs 0% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  • 72.4% vs 1.7% 400 mg · wk 12 · n 58 · Phase 2 · primary NCT00245765
  • 52.5% vs 1.7% 200 mg · wk 12 · n 59 · Phase 2 · primary NCT00245765

DLQI, change

adalimumab
-4.8 vs -4.2−0.6 vs placebowk 16 · n 49NCT00735787
3 other results
  • -7.9 vs -3.7 wk 12 · n 33 · Phase 4 · secondary NCT01553058
  • -4.1 vs -3.1 wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • -4.3 vs -3.4 wk 2 · n 49 · Phase 4 · secondary NCT00735787
certolizumab pegol
-10 vs -3.8−6.2 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
5 other results
  • -10.2 vs -3.3 400 mg Q2W · wk 16 · n 88 · Phase 3 · secondary NCT02326298
  • -6.8 vs -0.3 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • -10.4 vs -3.8 200 mg Q2W · wk 16 · n 90 · Phase 3 · secondary NCT02326272
  • -9.3 vs -3.3 200 mg Q2W · wk 16 · n 95 · Phase 3 · secondary NCT02326298
  • -6.8 vs -0.3 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. adalimumab: 11 of 11 rows · certolizumab pegol: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
certolizumab pegol
Rows use multiple source trials
BSA Involvement
absolute value · percentage points
Induction
5.9% (n=15) vs 10.7% (n=15) Methotrexate (MTX) @ 16wka,b,c,d
NCT00932113 · Phase 4 · registry result, not featured evidence
5.6% (n=54) vs 28.8% (n=40) placebo @ 12wk400 mge,a,b,c,d
NCT00245765 · Phase 2 · registry result, not featured evidence
show 1 more dose
7.1% (n=53) vs 28.8% (n=40) placebo @ 12wk200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
PASI
percent change · % of baseline
No placebo or comparator arm
-81.74% (n=50) @ 12wka,b,c
NCT01644396 · Phase 4 · registry result, not featured evidence
1 other source trial
-45% (n=10) @ 12wk
NCT02533375 · Phase 3 · registry result, not featured evidence
90.6% (n=37) @ 12wk400 mge,a,b,c
NCT00329303 · Phase 2 · registry result, not featured evidence
show 7 more doses
91.78% (n=35) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
87.94% (n=37)400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
87.59% (n=35) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
92.45% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
84.11% (n=32) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
83.46% (n=34)200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
78.75% (n=32) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
PASI 50
responder rate · % of participants
Induction
42.9% (n=49) vs 21.7% (n=23) placebo @ 16wk*a,b,c,d
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 21 subjects as posted
1 other source trial
91% (n=267) vs 93.4% (n=271) EU RPP @ 16wk*
NCT02581345 · Phase 3 · registry result, not featured evidence · converted to % from 243 Participants as posted
93.1% (n=58) vs 11.9% (n=59) placebo @ 12wk400 mge,a,b,c,d
NCT00245765 · Phase 2 · registry result, not featured evidence
show 1 more dose
86.4% (n=59) vs 11.9% (n=59) placebo @ 12wk200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
PASI 50
responder rate · % of participants
No placebo or comparator arm
88% (n=50) @ 12wka,b,c
NCT01644396 · Phase 4 · registry result, not featured evidence
3 other source trials
50% (n=10) @ 12wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
87.6% (n=89) @ 12wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 78 Participants as posted
93.1% (n=58) @ 12wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 54 Participants as posted
89.2% (n=37) @ 12wk400 mge,a,b,c
NCT00329303 · Phase 2 · registry result, not featured evidence
show 3 more doses
89.2% (n=37) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
76.5% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
67.6% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
PASI 75
responder rate · % of participants
No placebo or comparator arm
76% (n=50) @ 12wka,b,c
NCT01644396 · Phase 4 · registry result, not featured evidence
3 other source trials
20% (n=10) @ 12wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
60.7% (n=89) @ 12wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 54 Participants as posted
77.6% (n=58) @ 12wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 45 Participants as posted
86.5% (n=37) @ 12wk400 mge,a,b,c
NCT00329303 · Phase 2 · registry result, not featured evidence
show 3 more doses
75.7% (n=37) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
67.6% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
50% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
PASI 90
responder rate · % of participants
No placebo or comparator arm
48% (n=50) @ 12wka,b,c
NCT01644396 · Phase 4 · registry result, not featured evidence
3 other source trials
10% (n=10) @ 12wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
34.8% (n=89) @ 12wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 31 Participants as posted
50% (n=58) @ 12wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 29 Participants as posted
48.6% (n=37) @ 12wk400 mge,a,b,c
NCT00329303 · Phase 2 · registry result, not featured evidence
show 3 more doses
40.5% (n=37) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
35.3% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
29.4% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
sPGA 0/1
responder rate · % of participants
No placebo or comparator arm
72% (n=50) @ 12wka,b,c
NCT01644396 · Phase 4 · registry result, not featured evidence
4 other source trials
34% (n=50) @ 12wk*
NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 17 Participants as posted
31.4% (n=35) @ 12wk*
NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
50% (n=366) @ 12wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
64.8% (n=364) @ 12wk
NCT00574249 · Phase 3 · registry result, not featured evidence
56.8% (n=37) @ 12wk400 mge,a,b,c
NCT00329303 · Phase 2 · registry result, not featured evidence
show 1 more dose
52.9% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
Dropout rate
41.3%f
NCT00195676 · Phase 3
show 35 more results
6.7%
NCT00932113 · Phase 4 · registry result, not featured evidence
3%
NCT01553058 · Phase 4 · registry result, not featured evidence
0%
NCT01644396 · Phase 4 · registry result, not featured evidence
4.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
16.3%
NCT00735787 · Phase 4 · registry result, not featured evidence
9.4%
NCT05637515 · Phase 3 · registry result, not featured evidence
50%
NCT02533375 · Phase 3 · registry result, not featured evidence
5.2%Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
13.8%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
21.1%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
33.3%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
1.5%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
11%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
4.9%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
17.2%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
2%Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
2.9%Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
7.7%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
7.1%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
11.8%40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
22.4%80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
24.7%40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
0%
NCT01872546 · Phase 2 · registry result, not featured evidence
11.1%
NCT01320293 · Phase na · registry result, not featured evidence
—400 mg Q2Wf
NCT02326272 · Phase 3
show 20 more results
—200 mg Q2W
NCT02326272 · Phase 3
—400 mg Q2W
NCT02326298 · Phase 3
—200 mg Q2W
NCT02326298 · Phase 3
—400 mg Q2W
NCT02346240 · Phase 3
—400 mg Q4W
NCT02346240 · Phase 3
—200 mg Q2W
NCT02346240 · Phase 3
—400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—200 mg Q2W + 400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination
—200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—All CZP (SS)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
5.4%400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
5.9%200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
13.8%400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
23.7%200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
5.6%f
NCT00195676 · Phase 3
show 35 more results
—
NCT00932113 · Phase 4 · registry result, not featured evidence
—
NCT01553058 · Phase 4 · registry result, not featured evidence
—
NCT01644396 · Phase 4 · registry result, not featured evidence
—
NCT01265823 · Phase 4 · registry result, not featured evidence
—
NCT00735787 · Phase 4 · registry result, not featured evidence
—
NCT05637515 · Phase 3 · registry result, not featured evidence
20%
NCT02533375 · Phase 3 · registry result, not featured evidence
1%Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
4.6%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
2.6%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0.6%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
6.9%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
—Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
4.9%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
1.6%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
—40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
—80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
—40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
—
NCT01872546 · Phase 2 · registry result, not featured evidence
5.6%
NCT01320293 · Phase na · registry result, not featured evidence
—400 mg Q2Wf
NCT02326272 · Phase 3
show 20 more results
—200 mg Q2W
NCT02326272 · Phase 3
—400 mg Q2W
NCT02326298 · Phase 3
—200 mg Q2W
NCT02326298 · Phase 3
—400 mg Q2W
NCT02346240 · Phase 3
—400 mg Q4W
NCT02346240 · Phase 3
—200 mg Q2W
NCT02346240 · Phase 3
—400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—200 mg Q2W + 400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination
—200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—All CZP (SS)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
0%400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
1.7%200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Serious AEs
12.9%f
NCT00195676 · Phase 3
show 35 more results
0%
NCT00932113 · Phase 4 · registry result, not featured evidence
6.1%
NCT01553058 · Phase 4 · registry result, not featured evidence
0%
NCT01644396 · Phase 4 · registry result, not featured evidence
0.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
4.1%
NCT00735787 · Phase 4 · registry result, not featured evidence
1.7%
NCT05637515 · Phase 3 · registry result, not featured evidence
30%
NCT02533375 · Phase 3 · registry result, not featured evidence
—Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
1.4%Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
3.7%Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
7.3%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
3.2%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
0%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
5.7%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
7.7%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
1.2%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
4.9%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
3.4%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
0%Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
0%Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
4.4%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
4.1%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
—40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
19%80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
21.3%40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
0%
NCT01872546 · Phase 2 · registry result, not featured evidence
5.6%
NCT01320293 · Phase na · registry result, not featured evidence
8.1%400 mg Q2Wf
NCT02326272 · Phase 3
show 20 more results
14.1%200 mg Q2W
NCT02326272 · Phase 3
11.4%400 mg Q2W
NCT02326298 · Phase 3
7.4%200 mg Q2W
NCT02326298 · Phase 3
12.4%400 mg Q2W
NCT02346240 · Phase 3
11.4%400 mg Q4W
NCT02346240 · Phase 3
9.1%200 mg Q2W
NCT02346240 · Phase 3
9.4%400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
0%400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
2.8%200 mg Q2W + 400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination
2.8%200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
6.6%All CZP (SS)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
0%400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
8.8%400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
f
nasopharyngitis 26.6%
upper respiratory tract infection 20.3%
headache 11.2%
NCT00195676 · Phase 3
show 29 more results
upper respiratory tract infection 40%
dizziness 13.3%
flu-like symptoms 13.3%
NCT00932113 · Phase 4 · registry result, not featured evidence
upper respiratory infection 9.1% (placebo 12.9%)
joint range of motion decrease 6.1% (placebo 0%)
headache 3% (placebo 6.5%)
NCT01553058 · Phase 4 · registry result, not featured evidence
latent tuberculosis 8%
rhinitis 6%
alanine aminotransferase increased 2%
NCT01644396 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 11.3%
hyperglycemia 10.7%
arthralgia 6.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.5% (placebo 13%)
headache 14.3% (placebo 4.3%)
cough 8.2% (placebo 4.3%)
NCT00735787 · Phase 4 · registry result, not featured evidence
headache 2.2%
nasopharyngitis 2.2%
upper respiratory tract infection 2.2%
NCT05637515 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30%
pruritus 30%
hypoalbuminaemia 20%
NCT02533375 · Phase 3 · registry result, not featured evidence
injection site reaction 23.9%
nasopharyngitis 6.7%
headache 3.2%
NCT02581345 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
psoriasis 10.3%
injection site reaction 10%
NCT02581345 · Phase 3 · registry result, not featured evidence
EOW
upper respiratory tract infection 8.3% (placebo 8.3%)
headache 5.5% (placebo 0%)
nasopharyngitis 5.5% (placebo 9.3%)
NCT02016482 · Phase 3 · registry result, not featured evidence
EOW
nasopharyngitis 12.8% (placebo 9.3%)
upper respiratory tract infection 4.3% (placebo 8.3%)
depression 3.2% (placebo 0.9%)
NCT02016482 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 21.1%
headache 15.8%
dry skin 7.9%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 18.5%
back pain 11.1%
headache 11.1%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 28.7%
headache 25.3%
upper respiratory tract infection 14.9%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
nasopharyngitis 25.6%
headache 17.9%
cough 10.3%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
cough 18.2%
decreased appetite 9.1%
gastroenteritis 9.1%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
nasopharyngitis 23.1%
agitation 7.7%
cough 7.7%
NCT01251614 · Phase 3 · registry result, not featured evidence
Eow
upper respiratory tract infection 10.1% (placebo 6.9%)
oropharyngeal pain 4.1% (placebo 1.1%)
nasopharyngitis 3.8% (placebo 5.7%)
NCT01646073 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
cough 3.7%
headache 3.7%
NCT00566722 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.2%
injection site erythema 7.3%
nasopharyngitis 7.3%
NCT00566722 · Phase 3 · registry result, not featured evidence
fatigue 6.9%
pharyngitis 6.9%
abdominal pain 3.4%
NCT00566722 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18%
back pain 8%
common cold 8%
NCT00927069 · Phase 3 · registry result, not featured evidence
headache 11.4%
common cold 5.7%
upper respiratory tract infection 5.7%
NCT00927069 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.7%
headache 5.2%
psoriasis 5.2%
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
headache 6%
pruritus 5.8%
NCT00574249 · Phase 3 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.8%
upper respiratory tract infection 10.8%
headache 4.9%
NCT00513370 · Phase 3 · registry result, not featured evidence
80 mg every other week
nasopharyngitis 77.6%
blood triglycerides increased 29.3%
blood creatine phosphokinase increased 25.9%
NCT00647400 · Phase 2/3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 75.3%
blood triglycerides increased 24.7%
alanine aminotransferase increased 23.6%
NCT00647400 · Phase 2/3 · registry result, not featured evidence
upper respiratory tract infection 22.2%
elbow strain 5.6%
heartburn 5.6%
NCT01320293 · Phase na · registry result, not featured evidence
400 mg Q2Wf
nasopharyngitis 23.5%
upper respiratory tract infection 12.1%
psoriasis 8.1%
NCT02326272 · Phase 3
show 17 more results
200 mg Q2W
nasopharyngitis 19.4%
upper respiratory tract infection 11.2%
sinusitis 7.6%
NCT02326272 · Phase 3
400 mg Q2W
nasopharyngitis 30.5%
upper respiratory tract infection 15.6%
headache 8.4%
NCT02326298 · Phase 3
200 mg Q2W
nasopharyngitis 28.7%
upper respiratory tract infection 11.2%
arthralgia 7.4%
NCT02326298 · Phase 3
400 mg Q2W
nasopharyngitis 16% (placebo 11.7%)
upper respiratory tract infection 10.9% (placebo 10.2%)
hypertension 5.8% (placebo 5.5%)
NCT02346240 · Phase 3
400 mg Q4W
arthralgia 6.8% (placebo 2.3%)
blood creatine phosphokinase increased 6.8% (placebo 1.6%)
nasopharyngitis 6.8% (placebo 11.7%)
NCT02346240 · Phase 3
200 mg Q2W
nasopharyngitis 15% (placebo 11.7%)
upper respiratory tract infection 10.2% (placebo 10.2%)
viral upper respiratory tract infection 6.2% (placebo 1.6%)
NCT02346240 · Phase 3
400 mg Q2W
nasopharyngitis 43.8% (placebo 23.1%)
psoriasis 7.8% (placebo 23.1%)
dermatitis contact 6.3% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
400 mg Q4W
nasopharyngitis 30% (placebo 23.1%)
back pain 10% (placebo 0%)
dental caries 10% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
200 mg Q2W + 400 mg Q4W
nasopharyngitis 34.7% (placebo 23.1%)
psoriasis 11.1% (placebo 23.1%)
eczema 6.9% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination
200 mg Q2W
nasopharyngitis 31.9% (placebo 23.1%)
psoriasis 11.1% (placebo 23.1%)
eczema 6.9% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
nasopharyngitis 43.4% (placebo 23.1%)
psoriasis 10.7% (placebo 23.1%)
eczema 7.4% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
400 mg
headache 8.1%
nasopharyngitis 8.1%
asthenia 5.4%
NCT00329303 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 14.7%
psoriasis 11.8%
arthralgia 5.9%
NCT00329303 · Phase 2 · registry result, not featured evidence
400 mg
nasopharyngitis 21.1% (placebo 17.2%)
headache 14% (placebo 15.5%)
bronchitis 7% (placebo 5.2%)
NCT00245765 · Phase 2 · registry result, not featured evidence
200 mg
headache 21.7% (placebo 15.5%)
pruritus 11.7% (placebo 6.9%)
arthralgia 8.3% (placebo 3.4%)
NCT00245765 · Phase 2 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 16 weeks versus 12 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Target Lesion TOTAL 1.2 vs 3.4 Methotrexate (MTX) score @ 16wk
absolute change · score
NCT00932113 · Phase 4 · registry result, not featured evidence
Aortic Vascular Inflammation TBR -0.067 vs -0.052 placebo ratio @ 12wk
absolute change · ratio
NCT01553058 · Phase 4 · registry result, not featured evidence
Total Cholesterol Change mg/dL 1.48 vs 5 placebo mg/dL @ 12wk
absolute change · mg/dL
NCT01553058 · Phase 4 · registry result, not featured evidence
PASI 75 46.9% (n=32) vs 6.7% (n=30) placebo @ 12wk
responder rate · % of participants
PASI75
NCT01553058 · Phase 4 · registry result, not featured evidence · converted to % from 15 Participants as posted
PGA 0-1 43.8% (n=32) vs 6.7% (n=30) placebo @ 12wk
responder rate · % of participants
PGA Clear/Almost Clear
NCT01553058 · Phase 4 · registry result, not featured evidence · converted to % from 14 Participants as posted
EQ-5D 0.07 vs 0 placebo score @ 12wk
absolute change · score
NCT01553058 · Phase 4 · registry result, not featured evidence
PGA =0 0% (n=50) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 11 more results
0% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
6% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
20% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
60% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
70% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
39.3% (n=333) @ 16wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
42.9% (n=333) @ 19wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
45.6% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
36.6% (n=41) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
20.7% (n=29) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
12.2% (n=82) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted
PGA Improvement 40% (n=50) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 5 more results
74% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
98% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
98% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
100% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
96% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
PASI 100 0% (n=50) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 7 more results
0% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
2% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
20% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
50% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
64% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
24.2% (n=364) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence
15.3% (n=366) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
DLQI -60.04% (n=49) @ 8wk
percent change · % of baseline
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 12 more results
-75.03% (n=49) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
-79.16% (n=49) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
-71.46% (n=354) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence
-67.2% (n=363) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
-32.14% (n=346) @ 2wk
NCT00574249 · Phase 3 · registry result, not featured evidence
-47.49% (n=361) @ 2wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
-46.64% (n=354) @ 4wk
NCT00574249 · Phase 3 · registry result, not featured evidence
-60.93% (n=362) @ 4wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
-63.3% (n=354) @ 8wk
NCT00574249 · Phase 3 · registry result, not featured evidence
-62.3% (n=363) @ 8wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
-69.49% (n=354) @ 12wk
NCT00574249 · Phase 3 · registry result, not featured evidence
-66.75% (n=363) @ 12wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
NAPSI -68.06% (n=22) @ 24wk
percent change · % of baseline
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 2 more results
-40% (n=213) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence
-37.5% (n=212) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
DLQI Less Than or Equal 5 65% (n=150) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01265823 · Phase 4 · registry result, not featured evidence
show 1 more result
86% (n=150) @ 16wk
NCT01265823 · Phase 4 · registry result, not featured evidence

+ 169 further endpoints in the CSV export.

certolizumab pegol

PGA Clear or Almost Clear 2pt Improvement 71.6% (n=87) vs 2% (n=49) placebo @ 16wk400 mg Q2W
responder rate · % of participants
NCT02326272 · Phase 3
show 1 more result
66.8% (n=91) vs 2% (n=49) placebo @ 16wk200 mg Q2W
NCT02326272 · Phase 3
PGA Clear or Almost Clear 2pt Improvement 66.6% (n=87) @ 48wk400 mg Q2W
responder rate · % of participants
No placebo or comparator arm
NCT02326272 · Phase 3
show 1 more result
72.6% (n=91) @ 48wk200 mg Q2W
NCT02326272 · Phase 3
PGA 0 1 2pt Improvement 50.3% (n=167) vs 1.9% (n=57) placebo @ 12wk400 mg Q2W
responder rate · % of participants
NCT02346240 · Phase 3
show 3 more results
58.4% (n=167) vs 3.4% (n=57) placebo @ 16wk400 mg Q2W
NCT02346240 · Phase 3
39.8% (n=165) vs 1.9% (n=57) placebo @ 12wk200 mg Q2W
NCT02346240 · Phase 3
48.3% (n=165) vs 3.4% (n=57) placebo @ 16wk200 mg Q2W
NCT02346240 · Phase 3
PASI-75 Response Maintenance 88.6% (n=44) vs 100% (n=2) placebo @ 48wk400 mg Q4W
responder rate · % of participants
NCT02346240 · Phase 3
show 4 more results
98% (n=49) vs 100% (n=2) placebo @ 48wk400 mg Q2W
NCT02346240 · Phase 3
82% (n=50) vs 100% (n=2) placebo @ 48wk200 mg Q2W
NCT02346240 · Phase 3
79.5% (n=44) vs 100% (n=2) placebo @ 48wk200 mg Q2W
NCT02346240 · Phase 3
80% (n=50) vs 100% (n=2) placebo @ 48wk200 mg Q2W
NCT02346240 · Phase 3
Itch NRS -4 vs 0.2 placebo score @ 16wk400 mg Q2W
absolute change · score
NCT03051217 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-2.9 vs 0.2 placebo score @ 16wk200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
BSA 7% (n=37) @ 0wk400 mg
absolute change · percentage points
No placebo or comparator arm
NCT00329303 · Phase 2 · registry result, not featured evidence
show 29 more results
10% (n=37) @ 2wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
12% (n=37) @ 4wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
19% (n=35) @ 6wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
18% (n=36) @ 8wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
20.5% (n=34) @ 10wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
20.5% (n=34) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
22% (n=37)400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
0% (n=37) @ 2wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
3% (n=37) @ 4wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
7% (n=35) @ 6wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
9% (n=36) @ 8wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
9.5% (n=34) @ 10wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
10.5% (n=34) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
11% (n=37)400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
9% (n=34) @ 0wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
11% (n=34) @ 2wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
13% (n=34) @ 4wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
13.5% (n=34) @ 6wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
15% (n=33) @ 8wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
15% (n=32) @ 10wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
15% (n=32) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
15% (n=34)200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
2.5% (n=34) @ 2wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
4% (n=34) @ 4wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
7% (n=34) @ 6wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
10% (n=33) @ 8wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
12.5% (n=32) @ 10wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
10.5% (n=32) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
10% (n=34)200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
Time to Treatment Failure NA months400 mg
time to event · months
No placebo or comparator arm
NCT00329303 · Phase 2 · registry result, not featured evidence
show 1 more result
1.84 months*200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence · converted to months from 56 days as posted
Time to First Response 0.72 vs 1.86 placebo months400 mg
time to event · months
NCT00245765 · Phase 2 · registry result, not featured evidence · converted to months from 22 days as posted
show 1 more result
0.69 vs 1.86 placebo months*200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence · converted to months from 21 days as posted
Time to Response 1.82 vs 2.55 placebo months400 mg
time to event · months
NCT00245765 · Phase 2 · registry result, not featured evidence · converted to months from 55.5 days as posted
show 1 more result
1.4 vs 2.55 placebo months*200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence · converted to months from 42.5 days as posted
Time to Relapse 4.65 vs NA placebo months400 mg
time to event · months
NCT00245765 · Phase 2 · registry result, not featured evidence · converted to months from 20.14 weeks as posted
show 1 more result
5.11 vs NA placebo months*200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence · converted to months from 22.14 weeks as posted
Time to Treatment Failure 1.61 vs 1.38 placebo months400 mg
time to event · months
NCT00245765 · Phase 2 · registry result, not featured evidence · converted to months from 49 days as posted
show 1 more result
1.95 vs 1.38 placebo months*200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence · converted to months from 59.5 days as posted

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Rheumatoid Arthritismonoclonal antibody (fully human IgG1)
Reliable signal

NCT00195702 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).

Next expected readout: December 2027 · NCT06440629 (registry estimate)

Reported efficacy

Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)

Result source: NCT00195702

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Rheumatoid ArthritisPEGylated anti-TNF Fab' fragment
Weak signal

NCT03357471 · Phase 3 · completed

Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

Reported efficacy

Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Certolizumab Pegol Q2W Injection by e-Device (SS) 100 percentage of subjects (95% CI 91.3 to 100) | Certolizumab Pegol Q4W Injection by e-Device (SS) 96.88 percentage of subjects (95% CI 86 to 99.8)

Result source: NCT03357471

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabcertolizumab pegol
ACR2063.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
54.8% vs 23.9%+30.9 vs placebowk 24 · n 312NCT02151851
21 other results
  • 51.1% vs 25.9% wk 12 · n 851 · Phase 3 · primary NCT00717236
  • 77.6% vs 28.6% 400 mg · wk 12 · n 85 · Phase 2/3 · primary NCT00791999
  • 67.2% vs 14.9% 200mg · wk 12 · n 116 · Phase 3 · primary NCT00791921
  • 76.8% vs 28.6% 200 mg · wk 12 · n 82 · Phase 2/3 · primary NCT00791999
  • 62.5% vs 28.6% 100 mg · wk 12 · n 72 · Phase 2/3 · primary NCT00791999
  • 66.7% vs 27.5% 200mg · wk 24 · n 81 · Phase 3 · primary NCT00993317
  • 69% vs 61.5% wk 52 · n 655 · Phase 3 · secondary NCT01519791
  • 71.8% vs 24.7% 400 mg · wk 24 · n 85 · Phase 2/3 · secondary NCT00791999
  • 36.5% vs 15.3% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 63.8% vs 11.4% 200mg · wk 24 · n 116 · Phase 3 · secondary NCT00791921
  • 73.2% vs 24.7% 200 mg · wk 24 · n 82 · Phase 2/3 · secondary NCT00791999
  • 61.1% vs 24.7% 100 mg · wk 24 · n 72 · Phase 2/3 · secondary NCT00791999
  • 64.2% vs 37.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 86.5% vs 74.7% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 73.8% vs 74.7% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 65.2% vs 44.9% 400 mg · wk 34 · n 69 · Phase 4 · primary NCT00580840
  • 67.1% vs 44.9% 200 mg · wk 34 · n 70 · Phase 4 · primary NCT00580840
  • 61.5% vs 0% wk 12 · n 26 · Phase 4 · primary NCT01147341
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 54.5% vs 62.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
ACR5041.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
61.8% vs 52.6%+9.2 vs placebowk 52 · n 655NCT01519791
11 other results
  • 80.2% vs 68.4% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 36.5% vs 7.1% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 26.6% vs 9.9% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 20.8% vs 7.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 43.2% vs 20% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 25.9% vs 12.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 71.4% vs 68.4% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 52.2% vs 30.4% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 50% vs 30.4% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • 27.3% vs 37.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 19.2% vs 0% wk 12 · n 26 · Phase 4 · secondary NCT01147341
ACR7047.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
51.3% vs 39.9%+11.4 vs placebowk 52 · n 655NCT01519791
9 other results
  • 12.9% vs 2.8% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 13.6% vs 0% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 70.6% vs 60.8% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 16.7% vs 2.7% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 9.4% vs 3.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 17.3% vs 2.5% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 63.1% vs 60.8% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 37.7% vs 15.9% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 30% vs 15.9% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
DAS28-CRP remission38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
16% vs 5.7%+10.3 vs placebowk 12 · n 851NCT00717236
HAQ-DI, change-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
-1.0 vs -0.8−0.2 vs placebowk 52 · n 645NCT01519791
8 other results
  • -0.5 vs -0.2 wk 24 · n 306 · Phase 3 · secondary NCT02151851
  • -0.4 vs -0.2 wk 12 · n 826 · Phase 3 · secondary NCT00717236
  • -0.3 vs -0.0 200 mg · wk 24 · n 91 · Phase 3 · secondary NCT00674362
  • -0.5 vs -0.2 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • -0.5 vs -0.8 wk 16 · n 23 · Phase 3 · secondary NCT01235598
  • -0.6 vs -0.4 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • -0.7 vs -0.4 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
Modified Sharp score, change0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
0.4 vs 1.6−1.2 vs placebowk 52 · n 158NCT01451203
6 other results
  • 0.2 vs 1.8 wk 52 · n 528 · Phase 3 · secondary NCT01519791
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0.3 vs 0.9 wk 24 · n 158 · Phase 3 · secondary NCT01451203

ACR20

adalimumab
63.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
certolizumab pegol
54.8% vs 23.9%+30.9 vs placebowk 24 · n 312NCT02151851
21 other results
  • 51.1% vs 25.9% wk 12 · n 851 · Phase 3 · primary NCT00717236
  • 77.6% vs 28.6% 400 mg · wk 12 · n 85 · Phase 2/3 · primary NCT00791999
  • 67.2% vs 14.9% 200mg · wk 12 · n 116 · Phase 3 · primary NCT00791921
  • 76.8% vs 28.6% 200 mg · wk 12 · n 82 · Phase 2/3 · primary NCT00791999
  • 62.5% vs 28.6% 100 mg · wk 12 · n 72 · Phase 2/3 · primary NCT00791999
  • 66.7% vs 27.5% 200mg · wk 24 · n 81 · Phase 3 · primary NCT00993317
  • 69% vs 61.5% wk 52 · n 655 · Phase 3 · secondary NCT01519791
  • 71.8% vs 24.7% 400 mg · wk 24 · n 85 · Phase 2/3 · secondary NCT00791999
  • 36.5% vs 15.3% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 63.8% vs 11.4% 200mg · wk 24 · n 116 · Phase 3 · secondary NCT00791921
  • 73.2% vs 24.7% 200 mg · wk 24 · n 82 · Phase 2/3 · secondary NCT00791999
  • 61.1% vs 24.7% 100 mg · wk 24 · n 72 · Phase 2/3 · secondary NCT00791999
  • 64.2% vs 37.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 86.5% vs 74.7% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 73.8% vs 74.7% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 65.2% vs 44.9% 400 mg · wk 34 · n 69 · Phase 4 · primary NCT00580840
  • 67.1% vs 44.9% 200 mg · wk 34 · n 70 · Phase 4 · primary NCT00580840
  • 61.5% vs 0% wk 12 · n 26 · Phase 4 · primary NCT01147341
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 54.5% vs 62.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278

ACR50

adalimumab
41.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
certolizumab pegol
61.8% vs 52.6%+9.2 vs placebowk 52 · n 655NCT01519791
11 other results
  • 80.2% vs 68.4% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 36.5% vs 7.1% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 26.6% vs 9.9% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 20.8% vs 7.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 43.2% vs 20% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 25.9% vs 12.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 71.4% vs 68.4% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 52.2% vs 30.4% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 50% vs 30.4% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • 27.3% vs 37.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 19.2% vs 0% wk 12 · n 26 · Phase 4 · secondary NCT01147341

ACR70

adalimumab
47.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
certolizumab pegol
51.3% vs 39.9%+11.4 vs placebowk 52 · n 655NCT01519791
9 other results
  • 12.9% vs 2.8% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 13.6% vs 0% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 70.6% vs 60.8% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 16.7% vs 2.7% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 9.4% vs 3.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 17.3% vs 2.5% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 63.1% vs 60.8% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 37.7% vs 15.9% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 30% vs 15.9% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840

DAS28-CRP remission

adalimumab
38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
certolizumab pegol
16% vs 5.7%+10.3 vs placebowk 12 · n 851NCT00717236

HAQ-DI, change

adalimumab
-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
certolizumab pegol
-1.0 vs -0.8−0.2 vs placebowk 52 · n 645NCT01519791
8 other results
  • -0.5 vs -0.2 wk 24 · n 306 · Phase 3 · secondary NCT02151851
  • -0.4 vs -0.2 wk 12 · n 826 · Phase 3 · secondary NCT00717236
  • -0.3 vs -0.0 200 mg · wk 24 · n 91 · Phase 3 · secondary NCT00674362
  • -0.5 vs -0.2 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • -0.5 vs -0.8 wk 16 · n 23 · Phase 3 · secondary NCT01235598
  • -0.6 vs -0.4 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • -0.7 vs -0.4 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278

Modified Sharp score, change

adalimumab
0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
certolizumab pegol
0.4 vs 1.6−1.2 vs placebowk 52 · n 158NCT01451203
6 other results
  • 0.2 vs 1.8 wk 52 · n 528 · Phase 3 · secondary NCT01519791
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0.3 vs 0.9 wk 24 · n 158 · Phase 3 · secondary NCT01451203
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
30 other shared endpoints and safety

Coverage. adalimumab: 34 of 34 rows · certolizumab pegol: 34 of 34 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
certolizumab pegol
Rows use multiple source trials
ACR20
responder rate · % of participants
No placebo or comparator arm
97% (n=133) @ 52wk*a,b,c,d
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 129 participants as posted
show 1 more dose
80% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 4 participants as posted
81.3% (n=841)b,c,d
NCT00175877 · Phase 3
8 other source trials
83.3% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
76.7% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
90.7% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
70% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
81.7% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
74.2% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
58.1% (n=370) @ 52wk
NCT00160693 · Phase 3 · registry result, not featured evidence
57.2% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
ACR50
responder rate · % of participants
No placebo or comparator arm
88% (n=133) @ 52wk*a,b,c,d
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 117 participants as posted
show 1 more dose
40% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 2 participants as posted
57.6% (n=841)b,c,d
NCT00175877 · Phase 3
7 other source trials
58.3% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
62.8% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
69.8% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
40.9% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
48.9% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
47.4% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
27.6% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
ACR70
responder rate · % of participants
No placebo or comparator arm
65.4% (n=133) @ 52wk*a,b,c,d
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
show 1 more dose
0% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 0 participants as posted
38.2% (n=841)b,c,d
NCT00175877 · Phase 3
7 other source trials
16.7% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
58.1% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
46.5% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
22.7% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
26.2% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
25.5% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
7.7% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
All-Cause Discontinuation
event count · % of participants
0.2635% (n=353) vs 0.2247% (n=361) ADA+MTX @ 104wkb
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2635% (n=353) vs 0.2247% (n=361) ADA+MTX @ 104wkb
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
CDAI
absolute change · score
-26.3 vs -27.99 ABBV-3373 score @ 12wke,b,c
NCT03823391 · Phase 2 · registry result, not featured evidence
-18.96 vs -10.93 placebo score @ 12wke,b,c
NCT00717236 · Phase 3 · registry result, not featured evidence
CDAI Clinical Remission
responder rate · % of participants
55.2% (n=105) vs 48.2% (n=112) placebo @ 78wk*a,f,b,g
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
show 1 more dose
15.1% (n=259) vs 48.2% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
52.4% (n=84) vs 43% (n=79) placebo @ 104wkQ2Wa,f,b,g
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
55.6% (n=126) vs 43% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
CDAI Clinical Remission
responder rate · % of participants
No placebo or comparator arm
27.6% (n=98) @ 26wk20 mg MTXa,b,c,h
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
29.3% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
22% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
12.2% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
27.9% (n=122) @ 136wkb,c,h
NCT00843778 · Phase 3 · registry result, not featured evidence
CRP Change
absolute change · mg
-11.2 vs -13.5 Standard of Care mg @ 104wkf,b,c,i
NCT01162421 · Phase 4 · registry result, not featured evidence
0.55 vs 1.05 placebo mg @ 12wkf,b,c,i
NCT00717236 · Phase 3 · registry result, not featured evidence
DAS28
absolute change · score
-3.71 vs -3.04 placebo score @ 78wka,b,j
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-2.7 vs -3.04 placebo score @ 78wk
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
-3.04 vs -1.65 placebo score @ 34wk400 mga,b,j
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-2.83 vs -1.65 placebo score @ 34wk200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
DAS28 Low Disease Activity
responder rate · % of participants
58.8% (n=17) vs 54.8% (n=31) ABBV-3373 @ 12wke,b,c,k
NCT03823391 · Phase 2 · registry result, not featured evidence
48.8% (n=84) vs 39.2% (n=79) placebo @ 104wkQ2Wa,e,b,c,k
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 5 more doses
65.5% (n=84) vs 59.5% (n=79) placebo @ 104wkQ2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
70.2% (n=84) vs 68.4% (n=79) placebo @ 104wkQ2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
53.2% (n=126) vs 39.2% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
73.8% (n=126) vs 59.5% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
74.6% (n=126) vs 68.4% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
DAS28 Low Disease Activity
responder rate · % of participants
No placebo or comparator arm
60.2% (n=98) @ 26wk20 mg MTXa,l,m,b,c,n
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
56.6% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
44% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
42.9% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
32.3% (n=279) @ 52wka,l,m,b,c,n
NCT01255761 · Phase 4 · registry result, not featured evidence
show 3 more doses
24.9% (n=365) @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
31.5% (n=238) @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
21.5% (n=368) @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
DAS28 Remission
responder rate · % of participants
73.3% (n=105) vs 58.9% (n=112) placebo @ 78wk*a,b,j
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 77 Participants as posted
show 1 more dose
27.4% (n=259) vs 58.9% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 71 Participants as posted
29% (n=69) vs 5.8% (n=69) placebo @ 34wk400 mga,b,j
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
18.6% (n=70) vs 5.8% (n=69) placebo @ 34wk200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
DAS28-CRP
absolute change · score
-2.51 vs -2.65 ABBV-3373 score @ 12wke,b,c
NCT03823391 · Phase 2 · registry result, not featured evidence
-1.7 vs -0.84 placebo score @ 12wke,b,c
NCT00717236 · Phase 3 · registry result, not featured evidence
DAS28-ESR
absolute change · score
-2.8 vs -1.8 placebo score @ 26wkb,c,o
NCT00870467 · Phase 3 · registry result, not featured evidence
-3.901 vs -3.436 placebo score @ 104wkQ2Wa,b,c,o
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
0.511 vs 1.145 placebo score @ 104wkQ2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
-4.252 vs -3.436 placebo score @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
0.414 vs 1.145 placebo score @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
DAS28-ESR
absolute change · score
No placebo or comparator arm
-3.7 score @ 52wka,b,c,d
NCT00870467 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.9 score @ 52wk
NCT00870467 · Phase 3 · registry result, not featured evidence
-3.222 scoreb,c,d
NCT00175877 · Phase 3
3 other source trials
-2.14 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-2.26 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-2.99 score
NCT00160641 · Phase 3 · registry result, not featured evidence
DAS28-ESR LDAS
responder rate · % of participants
35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wka,b
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wka,b
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
DAS28-ESR Remission
responder rate · % of participants
30.4% (n=171) vs 14.7% (n=163) placebo @ 26wk*b,c,o
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 52 participants as posted
52.4% (n=84) vs 44.3% (n=79) placebo @ 104wkQ2Wa,b,c,o
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
63.5% (n=126) vs 44.3% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
DAS28-ESR Remission
responder rate · % of participants
No placebo or comparator arm
46.6% (n=133) @ 52wk*a,l,m,b,c
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 62 participants as posted
show 1 more dose
0% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 0 participants as posted
23.3% (n=279) @ 52wka,l,m,b,c
NCT01255761 · Phase 4 · registry result, not featured evidence
show 3 more doses
17.8% (n=365) @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
21.8% (n=238) @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
14.9% (n=368) @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
Erosion
absolute change · score
3 vs 6.4 Methotrexate score @ 104wka,b
NCT00195663 · Phase 3 · registry result, not featured evidence
show 1 more dose
1 vs 6.4 Methotrexate score @ 104wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
0 vs 0 placebo score @ 104wkQ2Wa,b
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
0 vs 0 placebo score @ 104wkQ2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
0 vs 0 placebo score @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
0 vs 0 placebo score @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
EULAR Good, Moderate
responder rate · % of participants
63% (n=64) vs 63% (n=64) AbbVie Adalimumab @ 24wkm,b,c
NCT03172325 · Phase 3 · registry result, not featured evidence
77.3% (n=22) vs 75% (n=8) placebo @ 24wk*m,b,c
NCT01147341 · Phase 4 · registry result, not featured evidence · converted to % from 17 participants as posted
HAQ-DI
absolute change · score
No placebo or comparator arm
-0.52 score @ 520wkb,c,d
NCT00195650 · Phase 3 · registry result, not featured evidence
-0.674 scoreb,c,d
NCT00175877 · Phase 3
2 other source trials
-0.567 score
NCT00160641 · Phase 3 · registry result, not featured evidence
-0.305 score
NCT00160693 · Phase 3 · registry result, not featured evidence
Modified Sharp
absolute change · score
No placebo or comparator arm
1.6 score @ 52wka,b,c,p
NCT00870467 · Phase 3 · registry result, not featured evidence
show 1 more dose
9.6 score @ 52wk
NCT00870467 · Phase 3 · registry result, not featured evidence
0.99 score @ 104wkb,c,p
NCT00160641 · Phase 3 · registry result, not featured evidence
mTSS no Progression
responder rate · % of participants
46.2% (n=39) vs 51.4% (n=35) Standard of Care @ 104wkf,b,c
NCT01162421 · Phase 4 · registry result, not featured evidence
79.2% (n=72) vs 69.3% (n=75) placebo @ 104wkQ2Wa,f,b,c
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
90.3% (n=72) vs 80% (n=75) placebo @ 104wkQ2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
77.9% (n=113) vs 69.3% (n=75) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
84.1% (n=113) vs 80% (n=75) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
Patient Global Assessment
absolute change · score
-23.6 vs -30.6 Standard of Care score @ 104wkb,c,q
NCT01162421 · Phase 4 · registry result, not featured evidence
-35.58 vs -16.37 placebo score @ 34wk400 mga,b,c,q
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-33.07 vs -16.37 placebo score @ 34wk200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
RAMRIS Synovitis
absolute change · score
-3.38 vs -3.88 placebo score @ 78wka,f,b,c,r
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-3.25 vs -3.88 placebo score @ 78wk
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
-0.4 vs 0.2 placebo score @ 2wkf,b,c,r
NCT01235598 · Phase 3 · registry result, not featured evidence
SDAI
absolute change · score
-27.42 vs -28.5 ABBV-3373 score @ 12wke,b,c
NCT03823391 · Phase 2 · registry result, not featured evidence
-19.66 vs -10.78 placebo score @ 12wke,b,c
NCT00717236 · Phase 3 · registry result, not featured evidence
SDAI Remission
responder rate · % of participants
52.4% (n=105) vs 45.5% (n=112) placebo @ 78wk*a,f,b,g
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 55 Participants as posted
show 1 more dose
15.1% (n=259) vs 45.5% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
53.6% (n=84) vs 41.8% (n=79) placebo @ 104wkQ2Wa,f,b,g
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
57.1% (n=126) vs 41.8% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
SDAI Remission
responder rate · % of participants
No placebo or comparator arm
37.9% (n=66) @ 48wk*maximum tolerated dosea,f,b,c,s
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 25 Participants as posted
show 3 more doses
39.7% (n=58) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
25.8% (n=120) @ 136wkf,b,c,s
NCT00843778 · Phase 3 · registry result, not featured evidence
SF-36 MCS
absolute change · score
7.1 vs 6.5 Methotrexate score @ 52wka,m,b,t
NCT00195663 · Phase 3 · registry result, not featured evidence
show 1 more dose
7.2 vs 6.5 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
5.51 vs 4.9 placebo score @ 34wk400 mga,m,b,t
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
8.59 vs 4.9 placebo score @ 34wk200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
SF-36 PCS
absolute change · score
12.6 vs 12.5 Methotrexate score @ 52wka,m,b,t
NCT00195663 · Phase 3 · registry result, not featured evidence
show 1 more dose
16.7 vs 12.5 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
10.54 vs 5.09 placebo score @ 34wk400 mga,m,b,t
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
9.65 vs 5.09 placebo score @ 34wk200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
Dropout rate
23.2%40 mg every other weeku
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
20.8%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
24.8%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
66.7%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
32.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
10.3%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
12.3%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
9.2%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
6.1%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
7%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
15.3%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
39.4%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
26.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
36%
NCT00690573 · Phase 3 · registry result, not featured evidence
9.4%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
62.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
5%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
8.2%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
11.2%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
47.6%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
4.1%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
2%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
9.1%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
64%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
—Q2Wv
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
—Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
41.3%
NCT00175877 · Phase 3
66.7%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
31.1%
NCT01443364 · Phase 4 · registry result, not featured evidence
47.7%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
49.3%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
3.7%
NCT01147341 · Phase 4 · registry result, not featured evidence
—400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
2.7%Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
—Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
2.4%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
4.2%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
—
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
55.8%
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
15.7%Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
11.8%Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
31.1%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
30.2%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
25%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
32.6%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
41.8%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
14.3%
NCT01235598 · Phase 3 · registry result, not featured evidence
26.7%
NCT00843778 · Phase 3 · registry result, not featured evidence
8.3%
NCT01374971 · Phase 3 · registry result, not featured evidence
39%
NCT00160641 · Phase 3 · registry result, not featured evidence
29.4%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
8.3%
NCT00753454 · Phase 3 · registry result, not featured evidence
9.4%
NCT00717236 · Phase 3 · registry result, not featured evidence
58.5%
NCT00160693 · Phase 3 · registry result, not featured evidence
12.5%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
29.3%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
23.5%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
19.5%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
29.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
30.3%
NCT04740814 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weeku
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
—20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
1.3%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
—
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
12.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
3.9%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
4.5%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
3.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
0%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
9.9%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
11.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
—
NCT00690573 · Phase 3 · registry result, not featured evidence
—DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
22.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
3%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
4.4%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
11%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
0%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
—Q2Wv
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
—Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
16.1%
NCT00175877 · Phase 3
—
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
—
NCT01443364 · Phase 4 · registry result, not featured evidence
11.7%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
7.9%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
—
NCT01147341 · Phase 4 · registry result, not featured evidence
—400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
0.9%Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
—Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
1.6%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
2.1%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
—
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
—
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
—Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
5.6%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
14%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
16.7%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
14%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
13.6%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
10.7%
NCT01235598 · Phase 3 · registry result, not featured evidence
11.5%
NCT00843778 · Phase 3 · registry result, not featured evidence
—
NCT01374971 · Phase 3 · registry result, not featured evidence
18%
NCT00160641 · Phase 3 · registry result, not featured evidence
4.7%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
2.4%
NCT00753454 · Phase 3 · registry result, not featured evidence
3.9%
NCT00717236 · Phase 3 · registry result, not featured evidence
24.1%
NCT00160693 · Phase 3 · registry result, not featured evidence
6.3%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
6.9%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
8.2%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
3.7%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
9.1%
NCT04740814 · Phase 1 · registry result, not featured evidence
Serious AEs
13%40 mg every other weeku
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
16%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
7.4%maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
4.5%reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
2.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
7.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
1%Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
0%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
13%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
10.3%
NCT01162421 · Phase 4 · registry result, not featured evidence
7.1%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
3.9%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
11.4%ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
6.9%ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
7.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
23.7%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
20.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
24%
NCT00690573 · Phase 3 · registry result, not featured evidence
4.1%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
51.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
1%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
4.9%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.3%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
6.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
1.9%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
35.9%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
12.5%Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
2.3%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
4.5%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
0%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
0%Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
0%New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
40%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
0%Q2Wv
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
0%Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
41.6%
NCT00175877 · Phase 3
0%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
13%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
12.1%
NCT01443364 · Phase 4 · registry result, not featured evidence
10.6%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
8.7%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
2.9%
NCT01147341 · Phase 4 · registry result, not featured evidence
2.9%400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
7.1%200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
1.8%Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
2%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
6.3%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
6.3%
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
10.6%
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
4.8%Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
7.1%Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
10.7%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
37.2%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
25%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
39.5%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
36.4%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
—
NCT01235598 · Phase 3 · registry result, not featured evidence
19.2%
NCT00843778 · Phase 3 · registry result, not featured evidence
0%
NCT01374971 · Phase 3 · registry result, not featured evidence
35.3%
NCT00160641 · Phase 3 · registry result, not featured evidence
9.4%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00753454 · Phase 3 · registry result, not featured evidence
6.1%
NCT00717236 · Phase 3 · registry result, not featured evidence
45.8%
NCT00160693 · Phase 3 · registry result, not featured evidence
5.2%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
11.2%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
5.9%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.9%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
6.1%
NCT04740814 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weeku
injection site pain 17.9% (placebo 21.5%)
upper respiratory tract infection 16.9% (placebo 11%)
headache 11.6% (placebo 5%)
NCT00195702 · Phase 3
show 40 more results
20 mg weekly
injection site pain 17.5% (placebo 21.5%)
upper respiratory tract infection 16.5% (placebo 11%)
headache 13.2% (placebo 5%)
NCT00195702 · Phase 3
maximum tolerated dose
liver function test abnormal 8.8%
abdominal pain upper 2.9%
dry mouth 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
reduced dose
dry mouth 3%
alanine aminotransferase increased 1.5%
cough 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
40 mg Eow
cough 2.7% (placebo 5%)
nasopharyngitis 2.7% (placebo 20%)
urinary tract infection 1.4% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.3% (placebo 20%)
upper respiratory tract infection 7.7% (placebo 0%)
hepatic enzyme increased 5.1% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.7% (placebo 20%)
arthralgia 5.9% (placebo 0%)
influenza 4.9% (placebo 10%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.3%
headache 10.7%
upper respiratory tract infection 10.3%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 25.6%
nasopharyngitis 20.5%
alanine aminotransferase increased 15.4%
NCT01162421 · Phase 4 · registry result, not featured evidence
high dose
nausea 10.3%
upper respiratory tract infection 7.7%
urinary tract infection 7.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
low dose
nausea 9.7%
fatigue 9.1%
upper respiratory tract infection 9.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
cough 6.7% (placebo 3.6%)
influenza 5.7% (placebo 2.7%)
nasopharyngitis 5.7% (placebo 3.6%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 11.2% (placebo 6.3%)
nasopharyngitis 8.9% (placebo 3.6%)
alanine aminotransferase increased 6.2% (placebo 2.7%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
injection site reaction 8.8%
headache 5.9%
nausea 5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
20 mg MTX
nasopharyngitis 11.2%
headache 9.2%
alopecia 8.2%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
10 mg MTX
nausea 13.1%
alopecia 6.1%
diarrhoea 6.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5 mg MTX
diarrhoea 6%
headache 6%
nasopharyngitis 6%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2.5 mg MTX
nausea 7.1%
arthralgia 6.1%
abdominal pain upper 4.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 22.6%
headache 21.5%
nausea 17.5%
NCT00195663 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30.2%
headache 20.5%
upper respiratory tract infection 18.7%
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 56%
upper respiratory tract infection 56%
influenza 32%
NCT00690573 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.2% (placebo 16.6%)
hepatic function abnormal 8.2% (placebo 5.5%)
alanine aminotransferase increased 7.6% (placebo 3.7%)
NCT00870467 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 46.3%
rheumatoid arthritis 25.4%
sinusitis 24.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
40 mg/0.8 mL
nasopharyngitis 4%
respiratory disorder 4%
headache 3%
NCT01231321 · Phase 3 · registry result, not featured evidence
40 mg every other week
nausea 5.5% (placebo 5.3%)
headache 4.9% (placebo 5.3%)
nasopharyngitis 4.9% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 6.6% (placebo 5.3%)
upper respiratory tract infection 2.6% (placebo 7%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
upper respiratory tract infection 3.2% (placebo 7%)
nasopharyngitis 2.7% (placebo 5.3%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
nausea 6.2% (placebo 5.3%)
upper respiratory tract infection 5.2% (placebo 7%)
headache 4.7% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg or 80 mg every other week
nasopharyngitis 60.2%
adverse drug reaction 29.5%
antinuclear antibody positive 15.9%
NCT00603993 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 45%
adverse drug reaction 23.6%
dna antibody positive 16.2%
NCT00235872 · Phase 3 · registry result, not featured evidence
40 mg EOW
upper respiratory tract infection 14% (placebo 11.7%)
injection site pruritus 5.8% (placebo 0%)
nasopharyngitis 5.8% (placebo 6.7%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
80 mg EOW
upper respiratory tract infection 12.4% (placebo 11.7%)
nasopharyngitis 7.4% (placebo 6.7%)
injection site pruritus 4.1% (placebo 0%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
urinary tract infection 11.8%
abdominal discomfort 5.9%
arthralgia 5.9%
NCT03823391 · Phase 2 · registry result, not featured evidence
nasopharyngitis 12.5%
bronchitis 6.3%
drug hypersensitivity 6.3%
NCT03823391 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 8.2%
NCT02565810 · Phase 2 · registry result, not featured evidence
nasopharyngitis 15.9%
rheumatoid arthritis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.6%
cystitis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 10%
cystitis 8%
nausea 8%
NCT01712178 · Phase 2 · registry result, not featured evidence
pharyngitis 1.6%
rash erythematous 1.6%
protein urine present 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
protein urine present 1.6%
pharyngitis 0%
rash erythematous 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 60%
diarrhoea 24%
pruritus 20%
NCT00235833 · Phase 2 · registry result, not featured evidence
v
hypertension 18.8%
nasopharyngitis 18.7%
urinary tract infection 17.7%
NCT00175877 · Phase 3
show 34 more results
nasopharyngitis 15.3%
headache 10.7%
upper respiratory tract infection 10.3%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
influenza 11.4%
arthralgia 6.8%
bronchitis 5.3%
NCT01443364 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 10.4%
urinary tract infection 10.4%
bronchitis 6%
NCT01255761 · Phase 4 · registry result, not featured evidence
urinary tract infection 10.6%
upper respiratory tract infection 10%
sinusitis 7.6%
NCT01255761 · Phase 4 · registry result, not featured evidence
upper respiratory infections 18.5% (placebo 0%)
rash 11.8% (placebo 0%)
bronchitis 8.8% (placebo 0%)
NCT01147341 · Phase 4 · registry result, not featured evidence
400 mg
upper respiratory tract infection 11.6% (placebo 14.5%)
urinary tract infection 8.7% (placebo 10.1%)
arthralgia 7.2% (placebo 2.9%)
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
200 mg
upper respiratory tract infection 7.1% (placebo 14.5%)
urinary tract infection 7.1% (placebo 10.1%)
arthralgia 1.4% (placebo 2.9%)
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 9.1% (placebo 5.3%)
headache 7.3% (placebo 13.2%)
nausea 5.5% (placebo 5.3%)
NCT00993668 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 15.5%
anaemia 5.6%
liver function test abnormal 4.4%
NCT02319642 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 13.7%
anaemia 5.3%
liver function test abnormal 5.3%
NCT02319642 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 15.8% (placebo 13.3%)
latent tuberculosis 7.6% (placebo 6.2%)
liver function test abnormal 7% (placebo 3.5%)
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
nausea 12.6% (placebo 10.1%)
upper respiratory tract infection 10.9% (placebo 5.1%)
urinary tract infection 7.3% (placebo 7.4%)
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
Q2W
urinary tract infection 6% (placebo 2.5%)
nasopharyngitis 4.8% (placebo 6.2%)
hypercholesterolaemia 2.4% (placebo 3.7%)
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
Q4W
nasopharyngitis 10.2% (placebo 6.2%)
hypercholesterolaemia 6.3% (placebo 3.7%)
latent tuberculosis 5.5% (placebo 0%)
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 44% (placebo 34.4%)
hepatic function abnormal 32.1% (placebo 30.6%)
nausea 24.5% (placebo 19.1%)
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
400 mg
nasopharyngitis 44.2%
pharyngitis 16.3%
bronchitis 14%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
rheumatoid arthritis 25%
bronchitis 16.7%
constipation 16.7%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 41.9%
eczema 27.9%
upper respiratory tract infection 20.9%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 38.2%
eczema 18.2%
pharyngitis 15.5%
NCT00850343 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.2%
diarrhoea 6.2%
nasopharyngitis 6.2%
NCT00843778 · Phase 3 · registry result, not featured evidence
flare of rheumatoid arthritis 8.3%
headache 8.3%
injection site reaction 8.3%
NCT01374971 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 16%
hypertension 13.6%
rheumatoid arthritis 13.4%
NCT00160641 · Phase 3 · registry result, not featured evidence
200mg
upper respiratory tract infection 14.1% (placebo 11.9%)
nasopharyngitis 11.8% (placebo 9.5%)
abdominal pain upper 5.9% (placebo 4.8%)
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 13.7%
NCT00753454 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.3% (placebo 5.3%)
headache 5.4% (placebo 5.3%)
rheumatoid arthritis 4.4% (placebo 7.7%)
NCT00717236 · Phase 3 · registry result, not featured evidence
nasopharyngitis 35.1%
upper respiratory tract infection 23.1%
back pain 22.4%
NCT00160693 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 10.4% (placebo 11.2%)
upper respiratory tract infection 6.3% (placebo 4.1%)
urinary tract infection 6.3% (placebo 5.1%)
NCT00674362 · Phase 3 · registry result, not featured evidence
200mg
nasopharyngitis 17.2% (placebo 14%)
rash 8.6% (placebo 0%)
eczema 5.2% (placebo 2.6%)
NCT00791921 · Phase 3 · registry result, not featured evidence
400 mg
nasopharyngitis 15.3% (placebo 11.7%)
hepatic function abnormal 5.9% (placebo 5.2%)
bronchitis 4.7% (placebo 1.3%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
200 mg
nasopharyngitis 13.4% (placebo 11.7%)
pharyngitis 6.1% (placebo 3.9%)
rash 4.9% (placebo 1.3%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
100 mg
hepatic function abnormal 11.1% (placebo 5.2%)
nasopharyngitis 11.1% (placebo 11.7%)
pharyngitis 6.9% (placebo 3.9%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence
upper respiratory tract infection 9.1%
nausea 6.1%
rheumatoid arthritis 6.1%
NCT04740814 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eTrial phases differ: Phase 2 versus Phase 3.
  6. fTrial phases differ: Phase 4 versus Phase 3.
  7. gAssessment timepoints differ: 78 weeks versus 104 weeks.
  8. hAssessment timepoints differ: 26 weeks versus 136 weeks.
  9. iAssessment timepoints differ: 104 weeks versus 12 weeks.
  10. jAssessment timepoints differ: 78 weeks versus 34 weeks.
  11. kAssessment timepoints differ: 12 weeks versus 104 weeks.
  12. lThe reported result categories differ.
  13. mTrial phases differ: Phase 3 versus Phase 4.
  14. nAssessment timepoints differ: 26 weeks versus 52 weeks.
  15. oAssessment timepoints differ: 26 weeks versus 104 weeks.
  16. pAssessment timepoints differ: 52 weeks versus 104 weeks.
  17. qAssessment timepoints differ: 104 weeks versus 34 weeks.
  18. rAssessment timepoints differ: 78 weeks versus 2 weeks.
  19. sAssessment timepoints differ: 48 weeks versus 136 weeks.
  20. tAssessment timepoints differ: 52 weeks versus 34 weeks.
  21. uPopulation comparability has not been reviewed for these studies.
  22. vPopulation comparability has not been reviewed for 39 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Sustained 8.7% (n=207) vs 1.5% (n=200) placebo40 mg every other week
responder rate · % of participants
NCT00195702 · Phase 3 · converted to % from 18 Participants as posted
show 1 more result
9.4% (n=212) vs 1.5% (n=200) placebo*20 mg weekly
NCT00195702 · Phase 3 · converted to % from 20 Participants as posted
Modified Sharp 0.09 vs 2.66 placebo score @ 52wk40 mg every other week
absolute change · score
Actual progression during study
NCT00195702 · Phase 3
show 1 more result
0.77 vs 2.66 placebo score @ 52wk20 mg weekly
Actual progression during study
NCT00195702 · Phase 3
HAQ-DI Less Than 0.5 58.8% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
mTSS no Progression 66.2% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
Time to Flare NA vs NA placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence
Disease Flare 36.3% (n=102) vs 45% (n=20) placebo
responder rate · % of participants
NCT02198651 · Phase 4 · registry result, not featured evidence
show 1 more result
15.4% (n=39) vs 8.6% (n=35) Standard of Care @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
Clinical Remission 10% (n=30) vs 12.5% (n=8) placebo @ 0wk
responder rate · % of participants
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
show 3 more results
46.7% (n=30) vs 12.5% (n=8) placebo @ 4wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 14 Participants as posted
56.7% (n=30) vs 37.5% (n=8) placebo @ 10wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted
43.3% (n=30) vs 50% (n=8) placebo @ 16wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted
Time to Clinical Remission 1.41 vs 4.15 placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to months from 6.1 weeks as posted
Rapid Radiographic Progression 2.6% (n=39) vs 14.3% (n=34) Standard of Care @ 52wk
responder rate · % of participants
NCT01162421 · Phase 4 · registry result, not featured evidence
Swollen Joint Count -9.2 vs -5.6 Standard of Care swollen joints @ 13wk
absolute change · swollen joints
NCT01162421 · Phase 4 · registry result, not featured evidence
show 5 more results
-10.4 vs -5.9 Standard of Care swollen joints @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-10.8 vs -8.1 Standard of Care swollen joints @ 39wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-11.3 vs -9.2 Standard of Care swollen joints @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-10 vs -9.4 Standard of Care swollen joints @ 78wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-10.6 vs -10.1 Standard of Care swollen joints @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
SJC28 -6.5 vs -4.6 Standard of Care swollen joints @ 13wk
absolute change · swollen joints
NCT01162421 · Phase 4 · registry result, not featured evidence
show 5 more results
-7.9 vs -4.5 Standard of Care swollen joints @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-8.3 vs -6.1 Standard of Care swollen joints @ 39wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-8.5 vs -6.9 Standard of Care swollen joints @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-8.1 vs -7.4 Standard of Care swollen joints @ 78wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-8.4 vs -7.6 Standard of Care swollen joints @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
Tender Joint Count -12.1 vs -9.3 Standard of Care tender joints @ 13wk
absolute change · tender joints
NCT01162421 · Phase 4 · registry result, not featured evidence
show 5 more results
-15.5 vs -8.3 Standard of Care tender joints @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-15 vs -11.2 Standard of Care tender joints @ 39wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-14.1 vs -13.4 Standard of Care tender joints @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-13.9 vs -13.4 Standard of Care tender joints @ 78wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-15.8 vs -15 Standard of Care tender joints @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence

+ 200 further endpoints in the CSV export.

certolizumab pegol

Morning Stiffness Duration -2.147 hours
absolute change · hours
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
-2.31 hours
NCT00160641 · Phase 3 · registry result, not featured evidence
EULAR Good 42.4% (n=834)
responder rate · % of participants
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
36% (n=556)
NCT00160641 · Phase 3 · registry result, not featured evidence
SF-36 PCS 8.813 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
6.628 score
NCT00160641 · Phase 3 · registry result, not featured evidence
SF-36 MCS 4.612 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
4.325 score
NCT00160641 · Phase 3 · registry result, not featured evidence
Sustained Clinical 69.1% (n=131) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT01443364 · Phase 4 · registry result, not featured evidence
show 5 more results
69.8% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
65.2% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
66.7% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
64.9% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
55.8% (n=131) @ 52wk
NCT01443364 · Phase 4 · registry result, not featured evidence
Clinical Response 64.7% (n=368) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT01255761 · Phase 4 · registry result, not featured evidence
show 1 more result
76.4% (n=365) @ 12wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
CDAI -23.79 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT01255761 · Phase 4 · registry result, not featured evidence
show 3 more results
-23.11 score @ 12wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-24.55 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-23.16 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
RAPID3 -6.78 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT01255761 · Phase 4 · registry result, not featured evidence
show 3 more results
-6.47 score @ 12wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-6.36 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-6.65 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
CDAI Low Disease Activity 34.8% (n=368) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT01255761 · Phase 4 · registry result, not featured evidence
show 3 more results
38.1% (n=365) @ 12wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
30.2% (n=368) @ 52wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
33.4% (n=365) @ 52wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
RAPID3 LDA 33.7% (n=368) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT01255761 · Phase 4 · registry result, not featured evidence
show 3 more results
33.4% (n=365) @ 12wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
27.7% (n=368) @ 52wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
28.8% (n=365) @ 52wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
RAPID3 Remission 14.9% (n=368) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT01255761 · Phase 4 · registry result, not featured evidence
show 3 more results
18.9% (n=365) @ 12wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
18.8% (n=368) @ 52wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
20.8% (n=365) @ 52wk
Yes
NCT01255761 · Phase 4 · registry result, not featured evidence
CDAI Decrease 10 84.6% (n=26) vs 22.2% (n=9) placebo @ 12wk
responder rate · % of participants
NCT01147341 · Phase 4 · registry result, not featured evidence · converted to % from 22 participants as posted
show 1 more result
81.8% (n=22) vs 75% (n=8) placebo @ 24wk*
NCT01147341 · Phase 4 · registry result, not featured evidence · converted to % from 18 participants as posted

+ 66 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · certolizumab pegol's landscape